ABCD
001-MCS -40-106_RD -03(17.0) / Saved on18Mar 2019Clinical Trial Protocol
TITLE PAGE
TITL E PAGE Document Number: c27983101-03
BI Trial No. 1407-0037
BI Investigational
Medicinal Product(s)BI 730357
TitlePartially -blind, randomized, parallel group, placebo and active 
comparator -controlled Phase I clinical trial to evaluate the 
photosensitivity  potential of BI 730357
Lay TitleEvaluation of photosafety  of BI 730357 compared to placebo and 
the known photosensitizing agent ciprofloxacin
Clinical PhasePhase I
Clinical Trial Leader
Tel.:
Principal 
Investigator
Tel: 
Version and Date Version: 3.0 Date: 01 Apr 2020
Page 1of 79
Proprietary confidential information .
2020 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved.
This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 2of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019CLINICAL TRIA L PROTOCOL SYNOPSIS
Company nameBoehringer Ingelheim
Protocol date 27 Sep 2019
Revision date 01 Apr 2020
BI trial number 1407-0037
Title of trial Partially -blind, randomized, parallel group, placebo and active 
comparator -controlled Phase I clinical trial to evaluate the 
photosensitivity  potential of BI 730357
Principal Investigator 
Trial site
Clinical phase Phase I
Trial rationale To evaluat e photosafet y of BI 730357
Trial objective(s) The objective of this trial isto evaluate the photosensitivity  potential 
of BI 730357 compared to placebo and a mild photosensitizer
ciprofloxacin aspositive control, assessed b y the Photosensitivity  
Index (PI ), changes in MED, ery thema, and local skin reactions 
following exposure to UVA and UVB radiation.
In addition, the relationship between the photosensitivity  response 
and pharmacokinetics of BI 730357 may be evaluated.
Trial e ndpoints The primary  endpoints are:
Phototoxicity  index at 24 h under condition 1
Phototoxicity  index at 24 h under condition 2
The secondary  endpoints are:
Phototoxicity  index at 10 min under condition 1
Phototoxicity  index at 1 h under condition 1
Phototoxicity  index at 10 min under condition 2 
Phototoxicity  index at 1 h under condition 2 
Minimum Ery thema Dose ( MED) percent change from baseline at 
10min, 1h, and 24h measured under condition 1 and condition 2
All endpoints are applicable for both treatment parts.
Trial design This is a partially  blind, randomized, parallel group, placebo -
controlled study conducted in two treatment arms. 
Treatment Part A will be conducted according to a randomized, 

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 3of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019double blind, placebo- controlled design to assess the photosensitivity  
potential, safety , tolerability , and pharmacokinetics of multiple doses 
of BI 730357. Subjects will be randomized in a 3:1 manner to receive 
BI 730357 or placebo.
Subjects will receive 400mg QD of BI 730357 or placebo over 8
days, or 300 mg BID of BI 730357 or placebo over 7 days with a 
single dose on day 8.Separate randomizations will be carried out for 
400 mg QD/placebo and 300 mg BID/placebo.
Photosensitivity  assessments will occur at baseline and following the 
last dose of either BI 730357 or placebo.
Treatment Part B will be conducted according to an open -label, 
observer -blinded design to assess the photosensitivity  potential of 
ciprofloxacin (a mild photosensitizer) as a positive control.
Subjects will receive 500 mg ciprofloxacin twice -daily  starting on
Day 3through to the morning of Day  8.
Photosensitivity  assessments will occur at base line and following the 
last dose of ciprofloxacin .
Total n umber of subjects
randomisedApproximately  84subjects will be enrolled to allow for at least 74
completed subjects
Number of subjects on 
each treatm ent36 subjects in Part A for 400 mg QD
36 subjects in Part A 300 mg BID
12 subjects in Part B  
Diagnosis Health y volunteers
Main in -and exclusion 
criteriaHealth y male and female subjects as determined by past medical 
history , phy sical examination, vital signs, electrocardiogram , and 
laboratory  tests at screening;
aged ≥18 to ≤55 y ears, with a BMI range: ≥18 to ≤ 35 kg/m 
Fitzpatr ick skin ty pe I, II, or III 
Fitzpatrick Skin Type Description:
I Alway s burns easily , never tans
II Alway s burns easil y, tans minimally
III Burns moderatel y, tans graduall y
Test product(s) BI 730357 100 mg tablets 
dose 400mg once daily 
300mg twice 
daily
mode of p.o.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 4of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019administration
Comparator product (s) Placebo matching BI 730357
dose Not applicable
mode of
administrationp.o.
Comparator product (s) Ciprofloxacin
dose 500mg twice daily
mode of
administrationp.o.
Duration of treatm ent BI 730357 tablets or matching placebo over 8days
Ciprofloxacin over 5 .5days
Statistical m ethods A mixed model for repeated measures on Phototoxicity  index ( PI)
values will be utilized for the anal ysis of primary  and secondary  
endpoints.  The model will include treatment (BI 730357, Placebo, 
ciprofloxacin), time (10min, 1h, 24h, 48h, and 72h), and treatment-
time interaction as fixed effects and subject as a rando m effect.  
Adjusted means and differe nces in PI  and 90% CIs for the contrast s
of interest (i.e. BI 703357 
–placebo at 24h) will be calculated from 
the model.
The anal ysis will be carried out separatel y for condition 1 and 
condition 2
Descriptive statistic s will be tabulated for all endpoints.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 5of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019FLOW CHART TREATMENT A400 MG QDDay
Planned time
[h:min]
Approx. time
[h:min]
Event and 
comment
Drug 
administration
Laboratory1
UVB/UVA 
irradiation
Photosensitivity 
assessment4
Physical Exam
12-lead ECG3
Vital signs 3
AE/Concomitant 
Medication
-28 
to 
-3Screening X X X X X
-3 X4X6X
-2 X7X5X
-1 Admission X X8X5X X X X
1-1:00 7:00Predose/
RandomizationX7
X
0:00 8:00 X
4:00 12:00 X
2 24:00 8:00 X X
3 48:00 8:00 X X
4 72:00 8:00 X X
5 96:00 8:00 X X
6 120:00 8:00 X X
7 144:00 8:00 X X
8 168:00 8:00 X X X
169:00 9:00
170:00 10:00 X
170:1 0 10:10 X
171:00 11:00 X
172:00 12:00
174:00 14:00
180:00 20:00
9 192:00 8:00 X
194:00 10:00 X
10 216:00 8:00 X
218:00 10:00 X
11 240:00 8:00 X X X X
242:00 10:00 Discharge X
15 EOT2X X X X X

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 6of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019FLOW CHART TREATMENT A 300 MG BIDDay
Planned time9
[h:min]
Approx. time 
[h:min]
Event and 
comment
Drug 
administration
Laboratory1
UVB/UVA 
irradiation
Photosensitivity 
assessment4
Physical Exam
12-lead ECG3
Vital signs 3
AE/Concomitant 
Medication
-28 
to 
-3Screening X X X X X
-3 X4X6X
-2 X7X5X
-1 Admission X X8X5X X X X
1-1:00 7:00Predose/
RandomizationX7
X
0:00 8:00 X
1:00 9:00
2:00 10:00
3:00 11:00
4:00 12:00 X
6:00 14:00
8:00 16:00
10:00 18:00
12:00 20:00 X
224:00 8:00 X X
36:00 20:00 X
348:00 8:00 X X
60:00 20:00 X
472:00 8:00 X X
84:00 20:00 X
596:00 8:00 X X
108:00 20:00 X
6120:00 8:00 X X
132:00 20:00 X
7144:00 8:00 X X
156:00 20:00 X
8 168:00 8:00 X X X
169:00 9:00
170:00 10:00 X

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 7of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Day
Planned time9
[h:min]
Approx. time 
[h:min]
Event and 
comment
Drug 
administration
Laboratory1
UVB/UVA 
irradiation
Photosensitivity 
assessment4
Physical Exam
12-lead ECG3
Vital signs 3
AE/Concomitant 
Medication
170:10 10:10 X
171:00 11:00 X
172:00 12:00
174:00 14:00
180:00 20:00
9 192:00 8:00 X
194:00 10:00 X
10 216:00 8:00 X
218:00 10:00 X
11 240:00 8:00 X X X X
242:00 10:00 Discharge X
15 EOT2X X X X X
1 For the laboratory tests performed at each particular visit refer to the Tables :5.2.3:1 and 5.2.3: 2
for Photosensitivity assessments refer to the sectio n 5.1.
2 Patients who discontinue trial treatment prematurely should undergo the End of Treatment (EOT) visit 
7days thereafter. 
3 Measurements of vital signs (BP; PR; BT) and ECG should precede blood sampling 
4 Photosensitivity assessment on day -2/-1 will be performed 10(+/-2)min, 1h (+/-5min), 24h (+/-
10min) after irradiation
5 Preliminary estimation of MED
6 Outpatient irradiation and baseli ne MED testing for Irradiation Condition 1 and Irradiation Condition 2 
will occur on Day -2. Tw o areas of the back will be defined for irradiation, follow ed by  MED 
assessments at 10 ±2 minutes, 1 hour ±5 minutes (Day -2) and at 24 hours ±10 minutes (Day -1) post 
irradiation.
7 Baseline irradiation for Irradiation Condition 3 will occur on Day - 1 with baseline inflammatory 
responses assessed at 10 ±2 minutes, 1 -hour ±5 minutes (Day -1) and at 24 hours ±10 minutes (Day 1) 
post Day -1 irradiation. 
8 Preliminary MED irradiation will be performed on Day -3 with confirninng evaluation on Day -2.
9 Planned time relative to the drug administration
10  samples should be taken before drug administration

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 8of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019FLOW CHART TREATMENT BDay
Planned time
[h:min]
Approx. time
[h:min]
Event and 
comment
Drug 
administration
Laboratory1
UVB/UVA 
irradiation 
Photosensitivity 
assessment
Physical Exam
12-lead ECG4
Vital signs 4
AE/Concomitant 
Mediation
-28 
to 
-3Screening X X X X X
-3 X4X6X
-2 X7X5X
-1 Admission X X8X5X X X X
1 0:00 8:00 Randomization X7X
2 24:00 8:00 X
3 48:00 8:00 X X
20:00 X
4 72:00 8:00 X X
20:00 X
5 96:00 8:00 X X
20:00 X
6 120:00 8:00 X X
20:00 X
7 144:00 8:00 X X
20:00 X
8 168:00 8:00 X X X
170:00 10:00 X
170:1 0 10:10 X
171:00 11:00 X
9 192:00 8:00 X
194:00 10:00 X
10 216:00 8:00 X
218:00 10:00 X
11 240 :00 8:00 X X X X
242:00 10:00 Discharge X
15 EOT2X X X X X
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 9of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20191 For the laboratory tests performed at each particular visit refer to the Tables :5.2.3: 1and 5.2.3: 2
for Photosensitivity assessments refer to the sectio n 5.1.
2 Patients who discontinue trial treatment prematurely should undergo the End of Treatment (EOT) visit 
7days thereafter. 
3 Measurements of vital signs (BP; PR ; BT) and ECG should precede blood sampling 
4 Photosensitivity assessment on day -2/-1 will be performed 10(+/-2)min, 1h (+/-5min), 24h (+/-
10min) after irradiation
5 Preliminary estimation of MED
6 Outpatient irradiation and baseli ne MED testing for Irradiation Condition 1 and Irradiation Condition 2 
will occur on Day -2. Tw o areas of the back will be defined for irradiation, follow ed by  MED 
assessments at 10 ±2 minutes, 1 hour ±5 minutes (Day -2) and at 24 hours ±10 minutes (Day -1) post 
irradiation.
7 Baseline ir radiation for Irradiation Condition 3 will occur on Day -1 with baseline inflammatory 
responses assessed at 10 ±2 minutes, 1 -hour ±5 minutes (Day -1) and at 24 hours ±10 minutes (Day 1) 
post Day -1 irradiation. 
8 Preliminary MED irradiation will be performed on Day -3 with confirming evaluation on Day -2.
9 Planned time relative to the drug administration
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 10of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019TABLE OF CONTENTS
TITLE PAGE ........................................................................................................................... 1
CLINICAL TRIAL PROTO COL SYNOPSIS ..................................................................... 2
FLOW CHART 
TREATMENT A 400 MG QD ................................................................... 5
FLOW CHART TREATMENT A 300 MG BID
.................................................................. 6
FLOW CHART 
TREATMENT B......................................................................................... 8
TABLE OF CONTENTS ...................................................................................................... 10
ABBREVIATIONS ................................................................................................................ 14
1. INTRODUCTION ............................................................................................... 17
1.1 MEDICAL BACKGROUND ............................................................................. 17
1.2 DRUG PROFILE ................................................................................................ 17
1.3 RATIONALE FOR PERFOR MING THE TRIAL ......................................... 21
1.4
BENEFIT - RISK ASSESSMENT ..................................................................... 21
1.4.1 Benefits ................................................................................................................. 21
1.4.2 Risks ..................................................................................................................... 21
1.4.3 Discussion ............................................................................................................. 26
2. TRIAL OBJECTIVES AND ENDPOINTS ...................................................... 28
2.1 MAIN OBJECTIVES, PRI MARY AND SECONDARY E NDPOINTS ........ 28
2.1.1 Main objectives .................................................................................................... 28
2.1.2
Primary endpoint(s)............................................................................................ 28
2.1.3 Secondary endpoint(s) ........................................................................................ 28
3.
DESCRIPTION OF DESIG N AND TRIAL POPULATI ON......................... 31
3.1 OVERALL TRIAL DESIGN ............................................................................. 31
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 
CONTROL GROUP(S) ...................................................................................... 32
3.3 SELECTION OF TRIAL P OPULATION ....................................................... 33
3.3.1 Main diagnosis for trial entry ............................................................................ 34
3.3.2
Inclusion criteria ................................................................................................. 34
3.3.3 Exclusion criteria ................................................................................................ 35
3.3.4
Withdrawal of patients from treatment or assessments.................................. 36
3.3.4.1 Discontinuation of trial treatment ......................................................................... 36
3.3.4.2
Withdrawal of consent to trial participation ......................................................... 37
3.3.4.3 Discontinuation of the trial by  the sponsor ........................................................... 37
4. TREATMENTS ................................................................................................... 38

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 11of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20194.1 INVESTIGATIONAL TREATMENTS ................................ ........................... 38
4.1.1 Identity of the Investigationa l Medicinal Products .......................................... 38
4.1.2 Selection of doses in the trial and dose modifications ...................................... 39
4.1.3 Method of assigning subjects to treatment groups .......................................... 39
4.1.4 Drug assignment and administration of doses for each patient ...................... 40
4.1.5
Blinding and procedures for unblinding ........................................................... 41
4.1.5.1
Blinding................................................................................................................. 41
4.1.5.2 Unblinding and breaking th e code ........................................................................ 42
4.1.6
Packaging, labelling, and re- supply ................................................................... 42
4.1.7 Storage conditions ............................................................................................... 42
4.1.8 Drug accountability
............................................................................................. 43
4.2 OTHER TREATMENTS, EM ERGENCY PROCEDURES, 
RESTRICTIONS ................................................................................................ 43
4.2.1 Other treatments and emergency procedures .................................................. 43
4.2.2
Restrictions .......................................................................................................... 43
4.2.2.1 Restrictions regarding concomitant treat ment ...................................................... 43
4.2.2.2 Restrictions on diet and life sty le.......................................................................... 44
4.2.2.3 Contracept ion requirements .................................................................................. 44
4.3 TREATMENT COMPLIANCE ........................................................................ 44
5. ASSESSMENTS .................................................................................................. 45
5.1 ASSESSMENT OF PHOTOS ENSITIVITY .................................................... 45
5.2 ASSESSMENT OF SAFETY ............................................................................. 47
5.2.1 Physical examination .......................................................................................... 47
5.2.2 Vital signs ............................................................................................................. 47
5.2.3 Safety laboratory parameters ............................................................................ 48
5.2.4 Electrocardiogram .............................................................................................. 51
5.2.5
Other safety parameters..................................................................................... 52
5.2.6 Assessment of adverse events ............................................................................. 52
5.2.6.1 Definitions of AEs ................................................................................................ 52
5.2.6.1.1 Adverse event ........................................................................................................ 52
5.2.6.1.2 Serious adverse event ............................................................................................ 52
5.2.6.1.3 AEs considered “Alway s Serious” ........................................................................ 53
5.2.6.1.4
Adverse events of special interest......................................................................... 53
5.2.6.1.5 Intensit y (severit y) of AEs .................................................................................... 54
5.2.6.1.6
Causal relationship of AEs.................................................................................... 54
5.2.6.2
Adverse event collection and reporting ................................................................ 55
5.2.6.2.1
AE Collection........................................................................................................ 55
5.2.6.2.2
AE reporting to the sponsor and timelines............................................................ 56
5.2.6.2.3 Pregnancy .............................................................................................................. 56
5.2.6.2.4
Exemptions to SAE reporting ............................................................................... 56
5.3 DRUG CONCENTRATION M EASUREMENTS AND 
PHARMACOKINETICS ................................................................................... 56
5.3.1 Assessment of pharmacokinetics ....................................................................... 56
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 12of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20195.3.2 Methods of sample collection ................................ ................................ ............. 57
5.4 ASSESSMENT OF BIOMAR KER(S) .............................................................. 58
5.5 BIOBANKING .................................................................................................... 58
5.6 OTHER ASSESSMENTS ................................................................................... 58
5.7 APPROPRIATENESS OF M EASUREMENTS .............................................. 58
6. INVESTIGATIONAL PLAN ............................................................................. 59
6.1 VISIT SCHEDULE ............................................................................................. 59
6.2 DETAILS OF TRIAL PRO CEDURES AT SELECTED VISITS ................. 59
6.2.1 Screening and run -in period(s) .......................................................................... 59
6.2.2 Treatment period(s) ............................................................................................ 60
6.2.3 Follow -
up period and trial completion.............................................................. 61
7. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE
............................................................................................................................... 62
7.1 NULL AND ALTERNATIVE HYPOTHESES ............................................... 62
7.2 PLANNED ANALYSES ..................................................................................... 63
7.2.1
General considerations ....................................................................................... 63
7.2.2 Primary endpoint analyses ................................................................................. 64
7.2.3 Secondary endpoint analyses ............................................................................. 64
7.2.5 Safety analyses ..................................................................................................... 65
7.2.6 Other Analyses .................................................................................................... 66
7.2.7 Interim Analyses ................................................................................................. 66
7.3 HANDLING OF MISSING 
DATA ................................................................... 66
7.4 RANDOMISATION ........................................................................................... 66
7.5 DETERMINATION OF SAM PLE SIZE ......................................................... 67
8. INFORMED CONSENT, TR
IAL RECORDS, DATA PR OTECTION, 
PUBLICATION POLICY, AND ADMINIST RATIVE STRUCTURE ........ 68
8.1 TRIAL APPROVAL, PATIENT INFORMATION, INF ORMED 
CONSENT ........................................................................................................... 68
8.2 DATA QUALITY ASSURAN
CE...................................................................... 69
8.3 RECORDS ........................................................................................................... 69
8.3.1 Source documents ............................................................................................... 69
8.3.2
Direct access to source data and documents..................................................... 70
8.3.3
Storage period of records ................................................................................... 70
8.4
EXPEDITED REPORTING OF  ADVERSE EVENTS .................................. 70
8.5 STATEMENT OF CONFIDE NTIALITY AND PATIENT PRIVACY ........ 71
8.5.1 Collection, storage and future use of biological samples and corresponding 
data ....................................................................................................................... 71
8.6 TRIAL MILESTONES ....................................................................................... 71
8.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL ................................... 72

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 13of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20199. REFERENCES ................................ ................................ ................................ ....73
9.1 PUBLISHED REFERENCES ............................................................................ 73
9.2 UNPUBLISHED REFERENC ES...................................................................... 73
10. APPENDICES ..................................................................................................... 74
10.1 RESTRICTED MEDICATIO N AND FOOD ................................................... 74
10.2 TIME SCHEDULE FOR PH ARMACOKINETIC (PK) B LOOD 
SAMPLING ......................................................................................................... 75
11. DESCRIPTION OF GLOBA L AMENDMENT(S) ......................................... 77
11.1 GLOBAL AMENDMENT 1 .............................................................................. 77
11.2 GLOBAL AMENDMENT 2 .............................................................................. 78
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 14of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019ABBREVIATIONS
AE Adverse Event
AESI Adverse Event of Special Interest
ALCOA Attributable, Legible, Contemporaneous, Original, Accurate 
ALT Alanine A minotransferase
AS Anky losing spondy litis
AST Aspartate Aminotransferase
b.i.d. (BID) bis in die (twice dail y dosing)
BI Boehringer Ingelheim
BP Blood Pressure
CA Competent Authority
CI Confidence Interval
CRA Clinical Research Associate
CRF Case Report Form , paper or electronic (sometimes referred to as “eCRF”)
CRO Contract Research Organisation
CT L eader Clinical Trial L eader
CT Manager Clinical Trial Manager
CTP Clinical Trial Protocol
CTR Clinical Trial Report
DBL Database Lock
DDI Drug Drug Interaction
DILI Drug Induced Liver Injury
EC Ethics Committee
ECG Electrocardiogram
eCRF Electronic Case Report Form
eDC Electronic Data Capture
EoT End of Treatment

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 15of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019EoTrial End of Trial
EudraCT European Clinical Trial s Database
FC Flow Chart
FOT Fully  Outcourced Trial
FUP Follow -up
GCP Good Clinical Practice
GMP Good Manufacturing Practice
HA
HIVHealth Authority
Human Immunodeficiency  Virus
i.v. intravenous
IB Investigator’s Brochure
IC Inhibitory  Concentration
IEC Independent Ethics Committee
IGRA Interferon- Gamma -Release -Assay
INN International Non -Proprietary  Name
IRB Institutional Review Board
IRT Interactive Response Technology
ISF Investigator Site File
IUD Intrauterine D evice
IUS Intrauterine Hormone -Releasing S ystem
LPLT Last Patient Last Treatment
LPLV
MEDLast Patient Last Visit
Minimum Ery thema Dose
MedDRA Medical Dictionary  for Drug Regulatory  Activities
MRD Multiple Rising Dose 
NOAEL No Adverse Effect Level
OPU Operative Unit
p.o. per os (oral)
PK Pharmacokinetics
PR Puls Rate
PsA Psoriatic Arthritis
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 16of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019PsO
QD (q.d.)Plaque Psoriasis
Once dail y
REP Residual Effect Period
s.c. subcutaneous
SAE Serious Adverse Event
SC Steering Committee
SOP Standard Operating Procedure
SRD Single Rising Dose
SUSAR Suspected Unexpected Serious Adverse Reactions
TMF Trial Master File
ULN Upper Level of Normal
WHO World Health Organisation
WOCBP Wom an of childbearing potential

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 17of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20191. INTRODUCTION
1.1 MEDICAL BACKGROUND
Retinoic acid -related orphan receptor γt (ROR ) γt is a nuclear hormone receptor/transcription 
factor expressed in Th17 cells and in distinct subsets of l ymphoid cells including natural 
killer (NK) cells, innate ly mphoid cells (ILCs), and  T cells. Upon cell activation, in 
response to multiple activation signals including cy tokines and T cell receptor engagement,
ROR γt regulates the transcription of IL-17A, IL-17F, IL -22 genes, and of the IL -23 receptor 
gene. Emerging clinical science indicates a pivotal role for th e Th17 axis in the pathogenesis 
of psoriasis (PsO) and other immunologicall y-mediated diseases. By  blocking ROR γ t-
mediated transcription of pro -inflammatory  cytokines and IL-23R, and consequently  their 
downstream signaling, ROR γt antagonism could prove effica cious in the treatment of Th17-
mediated diseases.
1.2 DRUG PROFILE
Boehringer Ingelheim (BI) is developing the new chemical entit y (NCE) , ROR γtantagonist
BI 730357, for the treatment of patients with plaque PsO, and other disease indications (e.g., 
psoriatic arthritis (PsA), anky losing spo
ndylitis (AS) , axial spondy loarthritis (axSpA),
Crohn’s disease (CD), and non -alcoholic steatohepat itis (NASH).
Mode of action
BI 730357 binds in the ligand -binding domain (LBD) of ROR γt and inhibits co -activator 
peptide recruitment, thereby  bloking the RORγt -mediated transcription of pro inflammatory  
cytokines, and of IL -23R.
Residual Effect Period
The Residual Effect Period (REP) of BI 730357 is 7 day s. Th is is the period after the last 
dose with measurable drug levels and/or pharmacody namic effects still likely  to be present.
Data from non -clinical studies and toxicology  studies
Relevant non -clinical pharmacology , PK, and toxicolo gy study  results are summarized 
below.
BI 730357 was profiled in cellular assay s in primary  human ce lls central to the pathogenesis 
underly ing PsO, PsA, and axSpA . BI 730357 provided consistent p otency  across all stimul i, 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 18of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019cell ty pes, and animal species tested, including in whole blood conditions. BI 730357 
provided substantial inhibition of disease -relevant biomarker and histology r eads in 
mechanistic preclinical in vivo mouse models of inflammation. The anticip ated huma n 
therapeutic exposure for BI 730357 was determined based on the effective plasma 
concentration required to reduce the tissue level of IL -17 by  80% in an IL-23 induced 
minicircle mouse model ( c09228382 Current version, n00250111 Current version]. The data 
showe d that 80% inhibition of tissue IL-17A mRNA at trough is required for maximal 
inhibition (>80%) of the histology  endpoints. The trough exposure was normalized using the 
mouse whole blood I C50.
Translating to humans using human whole blood IC50, the required trough for maximum 
effect on histology  endpoints for BI 730357 is 140 nM.
BI 730357 demonstrated good off- target selectivity ; exhibited low -level inverse -agonism 
against RORα, low- level ant agonism against hLXRα and low -level agonism activity  against 
hPXR. No activity  on RORβ was detected. No other off -target activities were detected.
The disposition of BI 730357 in rat, dog, and minipig is cha racterized by  low clearance and 
moderate volume o f distribution. Moderate -to-high oral bioa vailability  was observed across 
species. The plasma protein binding was high across all teste d species (mouse, rat, dog, and 
human), and there was no preferential partitioning into red bl ood cells. Biliary  excretion or 
fecal excretion was the major route of elimination of [14C] -BI 730357- derived radioactivity  
in rat and dog. In a quantitative whole body  autoradiograph y stud y in pigmented rats, [14C] -
BI 730357 -derived radioactivity  was mod
erately  distributed to tissues. Tissue -to-blood 
exposure ratios of radioactivity  into melanin -containing tissues of the ocular bulb was 
moderate to high.
In human hepatocy te incubations, approximately  90% of the metabolism of BI 730357 occurs 
via oxidation by CYP3A4 to an N -oxide metabolite (CD 6975). As such, concomitant 
medications that are inhibitors or inducers of CYP3A m ay cause clinically significant 
changes in BI 730357 exposure. Furthermore, data from in vitro studies indicate that 
BI 730357 may  cause clinically  relevant induction of CYP1A2 and CYP2B6 and inhibition 
of hepatic P -glycoprotein (P -gp) and renal MATE1 or MATE 2-K. In addition, inhibition of 
intestinal BCRP in humans is also possible at oral BI 730357 doses > 22 mg.
The toxicity  profile o
f BI 730357 has been assessed in safet y pharmac ology, genetic toxicity , 
embry o-fetal development, and repeat dose toxicity  studies up to 26 -and 39 -weeks in rat and 
dog, respectivel y. In general, BI 730357 appears to be well t olerated at clinically -relevan t 
plasma exposure in toxicity  studies. BI 730357 revealed n o evidence of teratogenicity  in 
embry o-fetal development studies in rats and rabbits. I n the repeat dose studies up to 26- and
39-weeks in rats and dogs, there were no effects on male or female rep roductive organs. 
BI 730357 is considered non -genotoxic. Based on long half -
lives of radioactivity  in dermal 
tissues and results from an in vitro and in vivo phototoxicity  assay , BI 730357 has 
phototoxicity  potential.
In summary , non- clinical BI 730357 safet y data demons trated an acceptable profile to 
support clinical trials in males and females, including women of childbearing potential
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 19of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019(WoCBP). Human exposures up to those achieved at the no observed adverse effect level
(NOAEL) of 5 mg/kg/day  in the 4 -and 13- weeks dog studies (C max6,660 nM, and AUC 0-24
127,400 nM•h in males and females combined) are considered safe for dosing up to 13 weeks 
in clinical trials. For clinical trials that exceed 13 week sduration, human exposures up to 
those achieved at the NOAEL of 1 mg/kg/day  in the 39 -weeks dog study  (C max1210 nM, and 
AUC 0
-2422,100 nM•h in males and females combined) are considered safe.
The nonclinical safet y package supports long -term administration of BI 730357 to human 
subjects, including WoCBP.
Data from clinical trials
Two clinical trials have been performed in healthy volunteers.
66 male adult subjects receiving BI 730357 in the Singl e Rising Dose stud y 1407.1. 
Safety  evaluations included phy sical examination, vital signs, ECG, laboratory  tests, and 
adverse events (AEs). AEs, which generally  reflected com monly -occurring events of short 
duration, and were mostly mild or moderate in severity , were distributed without discernible 
trend among recipients of placebo and risin g dose levels of BI 730357. No serious AEs
(SAEs) were reported.
Phase Ib trial 1407 -0002 evaluated MRD of BI 73035 7 ranging from 25 mg to 400 mg, 
administered as film -coated tablets to health y male adult subjects aged 18 to 45 years.
83subjects entered i nto the trial ; each group of 12 subjects was randomized (9 active: 3 
placebo) into one of 4 sequential dose groups under fasting conditions (25 mg, 50 mg, 100 
mg, 200 mg), and into one of 3 sequen tial dose groups under fed conditions (50 mg, 200 mg, 
and 400 mg). Comparison of the mean BI 730357 plasma concentrations indicated that 
exposure was related to dose , such that exposures increased with increasing dose. When BI 
730357 was administered to subjects in the fed state, higher
BI 730357 plasma levels and exp osures were observed, with a delay ed peak in concentrations 
compared to fasted conditions. Median t maxvalues ranged fr om 1.00 to 2.75 h in the fasted 
state and increased to 2.55 to 4.00 h in the fed state. Co
ncentrations following multiple 
dosing appea red to be approximately  double those following a single dose, with no relevant 
difference seen between 2 and 4 week profiles. Subject s were evaluated for safet y (physical 
examination, ECG and laboratory  studies, AEs, an d SAEs) and PK during once daily study 
drug treatment for 14 days (dose groups up to 100 mg) or 28 day s (200 mg and 400 mg dose 
groups), and for approximately  one week after completion of trea tment. Safety  data indicate 
that with respect to the kind, incidence and sev erity of the AEs, there w ere no notable 
differences among dose groups. The most frequently  reported AE s were headache in 26.5% 
and diarrhea in 10.8% of subjects, of subjects across BI 730357 dose groups . No SAEs were
reported during the trial. ECG 
recordings, clinical laboratory  evaluation, and vital signs 
showe d no clinicall y-relevant changes compared to baseline. Overall, administration of BI 
730357 to healthy  male subjects at doses up to 400 mg for up to 28 day s was well tolerated.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 20of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019A phase II trial ( 1407 -0030)in patients with moderate -to-severe chronic plaque psoriasis is 
ongoing, 178 patients were included and randomized in a blinded manne to receive 25 mg, 50 
mg, 100 mg, or 200 mg of BI 730357, or placebo, q.d., under fasted conditions, for 24 weeks. 
Primary analysis data from trial 1407 -0030 demonstrate thatPsO patients had higher 
exposure (up to 2.1 fold) compared to those of healthy  volunteers in 1407 -0002. Moreover, 
the exposures in PsO patients appear to be increasing with increasing dose, up to the highest 
(200 mg) dose evaluated, in a close to dose
-proportional manner.
Administration of BI 730357 to patients with moderate -to-severe plaque PsO at doses up to 
200 mg for at least 12 weeks has been well tolerated. Through Week 12, the overall 
frequency  ofpatients with at least 1 treatment emergent adverse events ( TEAE )was 50.6% 
for patients receiving BI 730357 (range 47.5% to 53.8%, vs. 55.0% of placebo recipients ). 
The most commonly  reported AEs, b y preferred term, were “upper respiratory tract infectio n” 
(10.1%, range 2.5% to 15.4%, vs. 15.0% among placebo recipients), “nasophary ngitis” 
(6.3%, range 5.0% to 7.7%, vs. 0% among placebo recipients), and “headache” (3.2%, range 
0% to 5.1%, vs. 0% among placebo recipients). ECG recordings, laboratories, and vital signs 
showed no clinicall y-relevant changes compared to baseline.
The non- clinical BI 730357 safet y data together with the safet y data from the t wo trials in 
healthy  volunteers (HV) and patients in plaque psoriasis demonstrated an acceptable profile 
to support clinic al trials in males and females, including WoCBP. These data justify  the oral 
dose of 4 00 mg BI 730357, taken once daily  and 300 mg BI 730357 taken twice dail y, over 8
daysin healthy  male and female volunteers. It is anticipated that higher mean BI 730357 
exposures as expected with 300 mg dosed b.i.d. under fed conditions for 8 day swill not 
exceed the NOAE Lthresholds observed in 13 week
sgeneral toxicity  studies .
For a more detailed description of the profile of BI 730357 please refer to the current
Investigator’s Brochure (IB) (c09228382).
Ciprofloxacin
CIPRO is a fluoroquinolone antibacterial indicated to treat or prevent infections that are 
proven or strongl y suspected to be ca used b y bacteria.
The absolute bioavailability  of ciprofloxacin when given as an oral tablet is approximately  
70% with no substantial loss by  first pass metabolism. 
Maximum serum concentrations are attained 1 to 2 hours after oral dosing. Steady -state C max
and AUC of Ciprofloxacin following administration of multiple oral doses to healthy  subjects 
are2.97 and 13.7 mcg•hr/mL respectivel y. When CI PRO Tablet is given concomitantly  with 
food, there is a delay  in the absorption of the drug, resulting in peak c oncentrations that occur 
closer to 2 hours after dosing rather than 1 hour .
For a more detailed description of the profile of Ciprofloxacin please refer to the
ciprofloxacin hy drochloride tablet U.S. prescribing information (R19-2246 andR19-3127).
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 21of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20191.3 RATIONALE FOR PERFOR MING THE TRIAL
BI 730357 is being developed for the treatment of patients with moderate-to- severe PsO, and 
other disease indications (e.g., psoriatic arthritis (PsA) axSpA, CD, and NASH )where there 
remains an unmet medical need .
Preclinical data indicate that BI 730357 has phototoxicity  potential. 
The current trial is being performed to assess the photosafet y of BI 730357 compared to 
placebo and t he known photosensitizing agent ciprofloxacin in healthy  volunteers.
Safety  data provided by  this trial will support further clinical development program of BI 
730357 in patients with diverse indications. 
1.4 BENEFIT - RISK ASSESSMENT
1.4.1 Benefits
Participation in this trial is without any  (therapeutic) benefit for healthy  subjects. Their 
participation in the trial, however, is of major importance to the development of BI 730357
and may help to generate future benefit for larger groups of patients with many  disease 
indications.
1.4.2 Risks
The subj ects are exposed to the risks related to the exposure to the trial medication and the 
risks of the trial procedures. 
Drug -related risks and safety  measures
BI 730357 
The pharmacological effects of BI 730357 are dose dependent, and no evidence for prolonged 
or irreversible effects has been observed. 
As described in Section 1.2 , the non- clinical BI 730357 safet y data together with the safet y 
data from trials in healthy  volunteers (HV) and patients with plaque PsO demonstrated an 
acceptable profile to support clinical trials in males and females, including WoCBP.
Since preclinical data indicate that BI 730357 has phototoxicity  potential, subjects in this trial 
will be kept in the clinic on all dosing day s upuntil completion of photosensitivity  
assessments 
72 hours after last dose and not allowed to expose themselves to the direct 
sunlight. Additionally , subjects will be advised to apply  protection measures up to the end of
trial visit ,as described in section 4.2.2.2 .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 22of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Preclinical data indicate that BI 730357 has DDI potential. During the trial , drugs or foods 
which are known strong or moderate inhibitors or inducers of CYP3A4, or drugs which are 
sensitive substrates of CYP1A2 or CYP2B6 will be prohibited. Additionally , substrates of 
P-gp are also to be excluded during the trial BI 730357 is confirmed as a sensitive 
cytochrome P450 (CYP) 3A substrate, based on clinica l drug- drug interaction (DDI) 
evaluation with itraconazole, a CYP3A inhibitor, in trial 1407 -0014. Drugs or foods that are 
known CYP3A inhibitors or strong or moderate CYP3A inducers should not be co -
administered in clinical trials with BI 730357. Based on in vitro data, BI 730357 could 
potentially  induce CYPs 1A2, 2B6, 2C8, 2C9, or 2C19 in human. Substrates of CYPs 1A2, 
2B6, 2C8, 2C9, or 2C19 for which a reduction in exposure could present a potential patient 
risk should not be given together with BI 73035 7.Additionally , based on in vitro data, BI 
730357 may  inhibit a number of transporters in human; b ased on the magnitudes of the in 
vitro inhibition, it is recommended that sensitive substrates of P -gp, BCRP, OATP1B1, 
OATP1B3, OAT3, OCT2, MATE1, and MATE2 -K that have narrow therap eutic windows 
should be avoided (refer to Appendix 10.1).
As with other immune -targeted therapies, impaired host defence is a theoretical target-related 
toxicity , potentially  resulting in increased risk of infection and/or malignancy . Subjects with 
latent TB infection or TB disease , also subjec ts with HBV, HCV ,HIVor any  other clinicall y 
relevant bacterial or fungal infection s
will be excluded at screening. 
Risk to subjects will also be minimized in this trial by  implementing conservative eligibility  
criteria. 
Homozy gous, but not heterozy gous RORC knockout mice have a high incidence of T cell 
lymphoma, thought to originate in the Thymus
. While the translatab ility of the knockout 
phenoty pe to pharmacological RORγ antagonism and to humans is unknown, this raises the 
hypothetical concern for clinical T cell l ymphoma risk. The exact cause of T cell ly mphomas 
in RORC knockout mice is not fully  understood, but chan ges in homeostasis in the thy mus, 
such as thy mocy te apoptosis and proliferation, are thought to play  a role. AEs and SAEs 
consistent with malignancy, and specificall y those representing l ymphoma, willbe carefully  
monitored and evaluated as well as monitor ing of peripheral blood ly mphocy te subsets will 
be integrated into this clinical trial.
An in vivo phototoxicity  study  in rats was conducted in pigmented rats. No cutaneous 
reactions indicative of phototoxic response were seen at 10 mg/kg/day , which corres ponded 
to mean C max and AUC 0
-24 values of 4,520 nM and 35,200 nM•h, respectively. No ophthalmic 
changes indicative of phototoxicity  were seen up to 30 mg/kg/day , which corresponded to a 
mean C maxand AUC 0-24 values of 13,500 nM and 107,000  nM•h, respectively .
Dose 400 mg BI 730357 planned to be tested in this study  was administered once dail y over a 
period of 4 weeks in the MRD study  1407-0002. The pharmacokinetic parameters observed 
in this study  -AUC 0-24 [nmol*h/L ] 15,600 ( AUC τ,ss [nmol*h/L ] 35,500) and Cmax [nmol/L ] 
1320 (C max,ss [nmol/L ] 2210 )indicate that the plasma concentrations and exposures, which 
might be achieved in this study , are lower than those observed in in vivo phototoxicity  study  
in rat where the phototoxic response shave been seen.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 23of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Ciprofloxacin
The most frequentl y reported adverse reactions, from clinical trials of all formulations, all 
dosages, all drug therap y durations, and for all indications of ciprofloxacin therap y were 
nausea (2.5%), diarrhoea (1.6%), liver function tests abnor mal (1.3%), vomiting (1%), and 
rash (1%).
Changes in laboratory  parameters while on CIPRO are listed below:
Hepatic -Elevations of ALT (SGPT), AST (SGOT), alkaline phosphatase, LDH, serum 
bilirubin.
Hematologic -Eosinophilia, leukopenia, decreased blood pla telets, elevated blood platelets, 
pancy topenia.
Renal -Elevations of serum creatinine, BUN, cry stalluria, cy lindruria, and hematuria have 
been reported.
Other changes occurring were: elevation of serum gammaglutam yl transferase, elevation of 
serum am ylase, reduction in blood glucose, elevated uric acid, decrease in hemoglobin, 
anemia, bleeding diathesis, increase in blood monocy tes, and leucocy tosis.
Fluoroquinolones, including CI PRO, have been associated with disabling and potentially  
irreversible serious adverse reactions from different body  systems that can occur together in 
the same patient. These adverse reactions include :
Tendinitis and Tendon Rupture 
Peripheral Neuropath y 
Central Nervous S ystem Effects 
Exacerbation of M yasthenia Gravis 
Other Serious and Sometimes Fatal Adverse Reactions 
Hypersensitivity Reactions 
Hepatotoxicity  
Serious Adverse Reactions with Concomitant Theophy lline 
Clostridium difficile Associated Diarrhea 
Prolongation of the QT Interval 
Musculoskeletal Disorders in Pediatric Patients 
Photosensitivity /Phototoxicity  
Development of Drug Resistant Bacteria 
These reactions can occur within hours to weeks after starting CI PRO. Patients of any  age or 
without pre-existing risk factors have experienced these adverse reactions. These events may  
be severe and generally  occur following the administration of multiple doses.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 24of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019As with all drugs, the potential for h ypersensitivity and allergic reactions has to be taken into 
consideration.
Although rar e, a potential for drug -induced liver injury  (DILI) is under constant surveillance 
by Sponsor s and regulators. Therefore, this trial requires timely  detection, evaluation, and
follow -up of laboratory  alterations in selected liver laboratory  parameters to e nsure patients´ 
safet y (see also section 5.2.6.1.4).
Special precautions
The following safet y measures will be applied in order t o minimize the risk for healthy  
volunteers:
Dose selection is based on a sound preclinical pack age, and safet y, tolerability  and PK 
data from M RD administration of BI 730357 up to 400 mg in health y volunteers and 
preliminary  safety  data for up to 200 mg in patients with plaque psoriasis.
Dose duration of 500 mg of ciprofloxacin bid over 5.5 day s is a standard, well 
tolerated clinical dose 
Individual stopping rules as described in secti on3.3.4.1 will be applied.
UV-light protection measures as described in sec tion 4.2.2 .2will be required until the
end of study  visit .
The subjects will be kept in a Phase I unit during trialmedication administration until 
completion of photosensitivity  assessments 72 hours after last dose for safety
evaluations. A careful clinical examination swill be performed during the trial, before 
the subjects are discharged from the clinic , and at the end of trial visit .
Adverse events, body  temperature , vital signs, ECGs and safet y laboratories will be 
monitor edat different time points during the trial . During the safety  follow -up period 
all AEs, regardless of relatedness, will be collected up to 7 daysafter the last 
administration of trial medication .
Procedure -related risks
Blood sampling b y venepuncture or through an indwelling venous catheter may  be 
accompanied b y mild bruising and also, in rare cases, by transient inflammation of the wall of 
the vein. In addition, in rare cases a nerve might be injured while inserting the venous 
catheter, potentially  resulting in paraesthesia , reduced sensibility , and/or pain for an indefinite 
period. 
The total volume of blood withdrawn per subject during this t rial will not exceed the volume 
of a normal blood donation (500 mL). No health-related r isk is expected from this blood 
withdrawal.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 25of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Based on the findings in the nonclinical studies conducted to date and in accordance with 
international regulatory  guidelines, the inclusion of wom en of childbearing potential 
(WoCBP) in this study  is justified. Tominimize the risk of unintentional exposure of an 
embry o or foetus to the investigational drug, Wo CBP must agree to the requirements for
pregnancy  testing and contraceptive methods described in this protocol. There are no specific 
contraceptive require ments for male participants.
Potential risks of clinical 
relevance for this trialSummary  of data, 
rationale for the riskMitigation strategy
Investigational Medicinal Product s:
Drug-induced liver 
injury (DILI)Rare but severe 
event, thus under 
constant surveillance 
by Sponsor s and 
regulators.Timely  detection, 
evaluation, and follow -up of 
laboratory  alterations in 
selected liver laboratory  
parameters to ensure 
patients´ safet y.
Drug interruption or 
discontinuation if 
applicable.
Infection and/or 
malignancy  Impaired host 
defence typical for 
immune -targeted 
therapiesSubjects with latent TB 
infection or TB disease at 
screening will be excluded.
Patients with HBV, HCV or 
HIV infection will be 
exclu ded. 
AEs and serious adverse 
events (SAEs) consistent 
with malignancy  or
infection sare to be 
evaluated
. 
Phototoxicity  potential Long persistence of 
BI 730357 in dermal 
tissues .
Known p hototoxicity  
potential of 
CiprofloxacinApply protection measures 
such as sunscreen and 
sunglasses during therapy
and up to 7 day s after last 
drug exposure . Prohibition 
oftreatment with ultraviolet 
light or medications with
known phototoxicity  
potential up to 7 day s after 
last drug exposure .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 26of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Potential risks of clinical 
relevance for this trialSummary  of data, 
rationale for the riskMitigation strategy
Investigational Medicinal Product s:
Hypersensitivity General pr ecautions Subjects with known 
hypersensitivity  to 
investigational drugs will be 
excluded at screening .
Discontinue investigational 
drugs immediatel y at the 
first appearance of a skin 
rash, jaundice, or an y other 
sign of h ypersensitivity  and 
supportive measures 
instituted .
Prolongation of the QT 
Interval Known potential of 
CiprofloxacinSubjects with known 
prolongation of the QT 
interval, risk factors for QT 
prolongation or torsade de 
pointes will be excluded at 
screening.
Trial procedures
Inflammation of the wall 
of the vein . Injuring of a 
nerve while inserting the 
venous catheter, 
potentially  resulting in 
paraesthesia , reduced 
sensibility , and/or pain 
for an indefinite period. General risk, 
acceptable in frame 
of the study  
participationEvaluation of the medical 
expertise of the trial sites is 
part of site feasibility  
assessment
1.4.3 Discussion
The nature of the target and the mechanism of action of BI 730357 as well as of 
Ciprofloxacin are well understood.
In the context of the unmet medi cal need and anticipated benefit of BI 730357, the benefit -
risk evaluation of the compounds, based upon preclinica l and clinical information available to 
date,is considered favourable andhealthy  subjects in this trial will not be exposed to undue 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 27of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019safet y risks in relation to the important information expected from this trial as a basis for 
further clinical development of BI730357. 
Cons
idering the medical need of the development of a better tolerated and more effective oral 
treatment for patients with PsO and other Th17- mediated diseases, the Sponsor considers that 
the benefit outweighs the potential risks and justifies exposure of health y human volunteers.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 28of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20192. TRIAL OBJECTIVES AND ENDPOINTS
2.1 M AIN OBJECTIVES , PRIMARY AND SECONDARY ENDPOINTS
2.1.1 Main objectives
The main objective of this trial is to evaluate the photosensitivity  potential of BI 730357 .
All endpoints are applicable for both treatment parts.
2.1.2 Primary endpoint(s)
The primary  endpoint s are:
Phototoxicity  index at 24 h under condition 1
Phototoxicity  index at 24 h under condition 2
Where 
condition 1 is full range solar UVB/UVA exposures and C ondition 2 is UVA exposure 
only.  Refer to Section 5.1 for the de tails of photosensitivity  assessments and these 
conditions.
Refer to Sec tion 7.2.2 for the endpoint definitions
2.1.3 Secondary endpoint(s)
Phototoxicity  index at 10 min under condition 1
Phototoxicity  index at 1 h under condition 1
Phototoxicity  index at 10 min under condition 2 
Phototoxicity  index at 1 h under condition 2 
MED percent c hange from baseline at 10min, 1h, and 24h measured under condition 1 
and condition 2
Where c ondition s 1 and 2 are described above in Section 2.1.2.
Refer to Section 7.2.3 for the endpoint definitions .

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 29of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 30of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 31of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20193. DESCRIPTION OF DESIG N AND TRIAL POPULATION
3.1 OVERALL TRIAL DESIGN 
The trial will be performed as p artiall y-blind, randomized, parallel group, placebo and active 
comparator controlled Phase I cl inical trial in healthy  male and female subjects aged 18 to 
55yearsin order to evaluate the photosensitivity  potential of BI 730357 compared to 
placebo and active comparator, and t o assess the relationship between the photosensitivity  
respons e and pharmacokinetics of the BI 730357. The subjects will be randomized to one of 
the two treatments parts 
(Treatment Part A or Treatment PartB).
In total, approximately  84healthy  male and female subjects (36 subjects each dose group in 
Treatment A; 12 subjects in Treatment B)are planned to be randomized in this trial to allow 
for at least 
74completed subjects.
Treatment Awill be conducted according to a randomized, double blind, placebo- controlled 
design to assess the photosensitivity  potential, safety  and tolerability , and pharmacokinetics 
of multiple doses of BI 730357. Subjects will be randomized in a 3:1 manner to receive BI 
730357 or placebo.
Subjects will receive 400mg of BI 730357 or placebo once dail yover 8 days, or 300 mg of BI 
730357 or placebo twice daily over 7 days with a single dose on day 8,in order to reach 
pharmacokinetic stead y state;  
Light exposure w ill occur 2 hours (+/-10 min) after the last dose of either IP or placebo, and 
on-treatment photosensitivity  assessments (determination of MED On drugand evaluation of 
erythema/local skin reactions) will be performed at 10 minutes, and 1, 24, 48, and 72 
hours 
after irradiation.
Treatment B will be conducted according to an open -label, observer
-blinded design to assess 
the photosensitivity  potential of ciprofloxacin (a mild photosensitizer) as a positive control.
Subjects will receive 500 mg ciprofloxacin starting on the morning of Day 3. Twelve (12) 
hours later, subjects received their second dose of 500 mg ciprofloxacin. Subjects continued a 
twice -daily dosing regimen through to the morning of Day 8to ensure they reached 
pharmacokinetic stead y state. 
Light exposure will occur on Day  8at 2 hours (+/-10 min) post-dose, and on- treatment 
photosensitivity  assessments (determination of MED On drug and evaluation of ery thema/local 
skin reactions) were performed at 10 minutes, and 1, 24, 48, and 72 hours after irradiation .
This trialwill have a screening period of up to 28 day s including preliminary  photosensitivity  
assessment onDay -3. Eligible subjects will undergo base line photosensitivity  assessment 
starting after i rradiation on day  -2 10 min, 1h, 24 hours after irradiation, and will be admit ted 
to the clinical site on Day  -1.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 32of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Subjects confirmed eligible will be dosed on Day  1 and be res ident until the Day  11.All 
subject s will remain in the clinic until day  11. The subject will then return to the clinic for 
ambulatory  visit approx. 7 days after the last drug administration for safet y follow up (e.o.t.
).
Additionally , all AEs, regardless of relatedness, will be collected until 7 days after the 
administration of trial medication. Adverse events not fully  resolved at the End of Trial visit 
willbe followed until recovery  or in case of persistency , sufficient characterization has been 
achieved and the investigator and medical monitor agree to not pursue them further.
For details 
for treatments to be administered refer to Section 4.1.
An overview of all relevant trial activities is provided in Flow Chart . For visit schedule and 
details of trial procedures at selected visits, refer to Section 6.1 and Section 6.2, respectivel y.
3.2 DISCUSSION OF TRIAL DESIGN, INCLUDING TH E CHOICE OF 
CONTROL GROUP(S)
This is an approximately 8 weeks Phase I trial in healthy volunteers consisting of the two 
treatment parts.
The design of this clinical phot osensitivity  study  followed the general concepts of ICH S10 (a 
recentl y published international guideline on “Photosafet y Evaluation of Pharmaceuticals” ), 
and included ciprofloxac in as a positive control (R19-2247). 
Three distinct exposure conditions were i ncluded to account for seasonal and regional 
differences in human exposure to sunlight.
A two- layer randomization process will be employ ed:
Allocation to the Study  part: Subjects will be randomly  allocated to part A or part B in a 3:1 
ratio in an open -label manner. Randomization numbers defining subject allocation to study  
part will be assigned in ascending, sequential order to eligible subjects.
Treatment Part A will be conducted according to a randomized, double blind, placebo-
controlled design. 
It is standard in trials involving health y volunteers to include a placebo group as control for 
the evaluation of safet y. Treatment Part A group will consist of 36 subj ectsin 400 mg QD 
group and 36 subjects in 300 mg BID group , with each group having 27 on active treatment 
and 9 on placebo.
The treatment will be blinded throughout the whole trial, to minimize any  bias that could be 
introduced b y knowledge of the treat ment by  either the investigator or the subject .
Treatment Part B will be conducted according to an open -label, observer -blinded design to 
assess the photosensitivity potential of ciprofloxacin (a mild photosensitizer) as a positive 
control.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101-
03 Clinical Trial Protocol Page 33of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201912 subjects will receive 500 mg ciprofloxacin b.i.d. over 5 day swith a single dose on the 6th
day.
The open- label treatment is not expected to bias the photosafet y results, since the trial
endpoints derived from the photosensitivity  assessments will be provided by anobserver
performing skin evaluations which is blinded to treatment allocation.
3.3 SELECTION OF TRIAL POPULATION
It is planned that in total up to 84healthy  male and female subjects will enter the trial. 
Subjects who prematurely discontinue the trial due to an
y reason may be replaced to ensure 
sufficient number complete the trial. Thus the planned number of subjects entered may  
exceed a total of 84. They  will be recruited from the volunteers’ pool of the trial site.
A log of all subjects enrolled int o the trial (i.e. who have signed informed consent) will be 
maintained in the Investigator Site File (ISF) irrespective of whether they have been treated 
with investigational drug or not.
If a subjects is enrolled in error (does not meet all inclusion crit eria or meets one or more 
exclusion criteria on the day  of enrolment), the sponsor should be contacted immediately .

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 34of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20193.3.1 Main diagnosis for trial entry
The trialwill be performed in healthy  male and female subjects.
Please refer to section 8.3.1 (Source Documents) 
for the documentation requirements 
pertaining to the in -and exclusion criteria.
3.3.2 Inclusion criteria
1.Health y male and female subjects according to the assessment of the Investigator, based 
on a complete medical history , phy sical examination (including dermatological skin ty pe 
assessment) , vital signs (blood pressure, pulse rate), 12- lead ECG, and clinical laboratory  
tests
2.18 to 55 y ears old
3.BMI 18 to 35 kg/m (incl.)
4.Fitzpatrick skin ty pe I, II, or III:
-I Alway s burns easily , never tans
-II Alway s burns easil y, tans minimally
-III Burns moderatel y, tans graduall y
5.No ultraviolet exposure of the test areas 4 weeks prior to baseline 
photo testing
6.Normal skin response during preliminary photo testing .
7.Signed and dated writte n informed consent in accordance with ICH-GCP and local 
legislation prior to admission to the trial.
8. Women of childbearing potential (WOC BP)1must be read y and able to use highl y 
effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less 
than 1% per yearwhen used consistently  and correctly .A list of contraception methods 
meeting these criteria is provided in the patient information
                                                
1A wo man is considered of childbearing potential (WOCBP) , i.e. fertile, following menarche and until becoming post-
menopausal unless permanently sterile. 
Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
Tubal l igation is NOT a method of permanent sterilisation.
A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 35of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20193.3.3 Exclusion criteria
1.Any finding in the medical examination (including blood pressure, pulse rate or ECG)
deviating from normal and judged as clinicall y relevant b y the Investigator .
2.Any laboratory  value outside the reference range that t he Investigator considers to be of
clinical relevance .
3.Gastrointestinal, hepatic, renal, respiratory , cardiovascul ar, metabolic, immunological or 
hormonal disorders or any evidence of a concomitant diseas
e judged as clinically  relevant 
by the Investigator .
4.Major surgery  (major according to the investigator’s assessment) performed within 10
weeks prior to randomisation or planned within 2 months after screening.
5.Any documented active or suspected malignancy  or history  of malignancy  within 5 y ears 
prior to screening, except appropriatel y treated basal cell carcinoma of the skin or in situ 
carcinoma of uterin e cervix .
6.Active skin disorders on the back where photosensitivity  testing will be performed .
7.
Subjects who must or wish to continue the intake of restricted medications (see section 
4.2.2.1) or an y drug considered likel y to int erfere with the safe conduct of the trial.
8. Subjects not expected to comply  with the protocol requirements or not expected to 
complete the trial as scheduled ( e.g. chronic alcohol or drug abuse or an y other condition 
that, in the investigator’s opinion, makes the subject an unreliable trial participant).
9.Currently  enrolled in another investigational device or drug trial, or less than 30 day s(or 
5 half -lives (whichever longer)) since ending another investigat ional drug trial.
10.Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
11.History  of relevant allergy  or hy persensitivity  (including allergy  to the trial medication or
its excipients) .
12. H istory  of hypersensitivity  to ciprofloxac in, any  member of the quinolone class of 
antibacterials.
13.History  of hypersensitivity  to sunlight or artificial source of intense light, especiall y UV 
light.
14.Chronic or acute infections which are of relevance in the opinion of the I nvestigator.
15. Positive res ult for HIV, HBV, and hepatitis C (Hep C) at screening.
16.History  of TB or positive finding in IGRA.
17.Unwillingness/inability  to refrain from intake of alcoholic beverages from 48 hours prior 
to the trial medication administration and until Day  7post trial medication administration.
18. Positive drug screening.
19.Blood donation of more than 500 mL within 30 days prior to administration of trial 
medication or intended donation during the trial .
20.Intention to perform excessive phy sical activities within 4daysprior to administration of 
trial medication or contact sport during the entire trialand unwilling to avoid vigorous 
exercise for 7 days post dosing.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 36of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201921.Inability  to compl y with dietary regimen of trial site .
22.Unwillingness to adhere to the rules of UV -light protect ion as described in section 4.2.2.
23. Received a live vaccination within 12 weeks prior to randomisation (visit 2), or an y plan 
to receive a live vaccination during the conduct of this trial.
24.Subjects with known prolongation of the QT interval, risk factors for QT prolongation or 
torsade de pointes.
3.3.4 Withdrawal of patient s from treatment or assessments
Subject s may discontinue trial treatment or withdraw consent totrial participation as a whole
(“withdrawal of consent”) with very  different implications; please see sections 3.3.4.1 a nd 
3.3.4.2 below.
Every effort should be made to keep thesubjects in the trial :if possible ontreatment , or at 
least to collect important trialdata.
Measures to control the withdrawal rate include c areful subjects’ selection, appropriate 
explanation of the trialrequirements and procedures prior to trial enrolment ,as well as the
explanation of the consequences of withdrawal. 
The decision to discontinue trial treatment or withdraw consent totrialparticipation andthe 
reason must be documented in the subject files and CRF. If applicable, consider the 
requirements for Adverse Event collection reporting (please see sections 5.2.6.2.1 and 
5.2.6.2 ).
3.3.4.1 Discontinuation of trial treatment
An individual subject will di scontinue trial treatment if:
The subject wants to discontinue trialtreatment , without the need to justify  the decision.
The subject has repeatedly  shown to be non -compliant with important trialprocedures 
and, in the opinion of both, the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements.
The subject needs to 
take concomitant medication that interfere s with the investigational 
medicinal product or other trial treatment listed in section 4.2.2 and appendix 10.1
The subject can no longer receive trial treatment for medical reasons ( such as surgery , 
adverse events, other diseases, or pregnancy ).
During the course of treatment the subject experience s any clinically significant adverse 
event (incl uding laboratory  abnormalities) . The phy sician may  disconti nue subjects at an y 
ti
me based on his or her clinical judgment.
If new efficacy /safet y information becomes available, Boehringer Ingelheim will review the
benefit -risk-assessment and, if ne eded, discontinue the trial treatment for all subjects or take 
any other appropriate action to gu arantee the safety  of the trial participants. 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 37of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Even if the trial treatment is discontinued, the subjects remain in the trial and, given their
agreement, will undergo the procedures for early  treatment discontinuat ion and follow -upas 
outlined in the Flow Chart and section 6.2.3.
For all participants, the reason for withdrawal from trial treatment (e.g., AE) must be 
recorded in the CRF. These data will be include d in t he trial database and reported. 
In case some subjects do not complete the trial, the cli nical trial lead together with the clinical 
project lead and the trial statistician willdecid e if and how man y subjects will be replaced. A 
replacement subject will be assigned to the same treatment as the subject he/she replaces.
3.3.4.2 W ithdrawal of consent totrial participation
Subjects may withdraw their consent to trial participation at an y time without the need to 
justify  the decision.
If a subject wants to withdraw consent, the investigator should be involved in the discussion 
with the subject and explain the difference between trial treatment discontinuation and 
withdrawal of consent totrial participation , as well as explain the options for continued 
follow -upafter trial treatment discontinuation , please see section 3.3.4.1 above .
3.3.4.3 Discontinuation of the trialby the s ponsor
Boehringer Ingelheim reserves the right to discontinue the trialoverall or at a particular trial
site at any  time for the following reasons:
1. Failure to meet expected enrolment goals overal l or at a particular trialsite.
2.Emergence of an y efficacy /safet y information invalidating the earlier positive benefit -
risk-assessm ent that could significantl y affect the continuation of the trial.
3.Deviations from GCP, the 
trial protocol , or the contract impairing the a ppropriate conduct 
of the trial .
Further follow up of subjects affected will occur as described in section 6.2.3 .
The investigator / the trialsite will be reimbursed for reasonable expenses incurred in case of 
trialtermination (except in case of the third reason).
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 38of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20194. TREATMENTS
4.1 I NVESTIGATIONAL TREAT MENTS
BI730357, Placebo to match BI 730357 .
Ciprofloxacin.
4.1.1 Identity of the Investigational Medicinal Products
Table 4.1.1:1 Test product 1
Substance:BI 730357
Pharmaceutical formulation:Film -coated tablet
Source:Boehringer Ingelheim Pharma GmbH & Co KG
Unit strength:100 mg
Posology :QDover 8 day s,or
BID over 7 day s with a single dose on day  8
Method and route of administration:Per os
Table 4.1.1:2 Test product 2
Substance:Placebo to match BI 730357
Pharmaceutical formulation:Film -coated tablet
Source:Boehringer Ingelheim Pharma GmbH & Co KG
Unit strength:NA
Posology :QDover 8 day s,or 
BID over 7 day s with a single dose on day  8
Method and route of administration:Per os
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 39of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Table 4.1.1:3 Comparator drug
Substance:Ciprofloxacin
Pharmaceutical formulation:Film -coated tablet
Source:
Unit strength:500 mg 
Posology :BID over 5 day s from day  3 with a single dose on 
day 8
Mode of administration:Per os
4.1.2 Selection of doses in the trial anddose modifications
The dose of 400 mg BI 730357 QD or 300 mg BID for this trial areselected on the basis of 
the PK and safet y data obtained in the SRD and MRD trials 1407.0001 and 1407 -0002, 
preliminary  PK an
dsafety  data obtained in patients with plaque psoriasis in the ongoing 
1407.30 study , combined with the preclinical data (see section 1.1), are intended to cover the 
highest therapeutic dose range (including safet y margin) chosen for the future clinical 
development of BI 730357 indiverse i ndications.
In the SRD tr ial, single dose levels up to 800 mg and in the MRD trial, multiple dose levels 
up to 400 mg were well tolerated in healthy  volunteers, and doses up to 200mg were well 
tolerat ed in plaque psoriasis patients .
Blinded photosafet y data will be evaluated b y the independent Investigator and BI medical 
team after completion of the 400 mg BI 730357 or placebo QDtreatment.
If no photo-safet y concerns h avebeen observed in the T reatment Agroup ,300 mg BI 730357 
or placebo BID will be conducted . 
The Ciprofloxacin dose selected in this trial reflects the standard clinical dose with acceptable
safet y profile. Ciprofloxacin was chosen as the positive control based on its property as mild 
photosensitizer (R 19 -2246, R 19 - 3127 ).
4.1.3 Method of assigning subject s to treatment groups
After the assessment of all in- and exclusion criteria, each eligible subject will be first 
randomly  allocated to part A 
400 mg QD or part B in a 3 : 1 ratio , where Part A is initially set 
of patients who will either receive BI 730357 400mg QD or placebo. 
Randomization list for this first step randomization process will be provided by  BI to the 
dedicated staff.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 40of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Consequently , subjects allocated to the treatment Part A will be randomised according to a 
randomisation plan in a 3:1ratio following the double blind design , which reflects the ratio of 
subjects re ceiving BI 730357 to placebo on Day  1.
Additionally , 12 subjects allocated to the treatment Part B will be assigned to receive 
Ciprofloxacin treatment.
A second set of 36 patients will be enrolled to either receive BI 730357 300mg BID or 
placebo.  These patients will be randomized using the same double blind design and 
procedures as described for Part A above (for BI 730357 400mg QD or placebo) and 
randomized in a 3:1 ratio to BI 730357 300mg BID or placebo. Randomiz ation list for this set 
of patients will also 
be provided by  BI to the dedicated staff .
The appropriate medication number will be assigned and documented in the CRF .
4.1.4 Drug assignment and administration of doses for each patient
The trial medication will be administered to the subjects as an oral dose together with about 
240 mL  of water under supervision of the investigating ph ysician 
or an authorised designee . 
To ensure a dosing interval of 24 and 12 hours for treatment group P art A and 12 hours in 
treatment Part B , the administration of trial medication should take place at the same time 
every  day within a deviation of no more than +/ -15 min . A standard continental breakfast 
(table 4.1.4:1 ) should be taken after blood sampling and before the stud y drug administration
(the s afety laboratory  samples will be taken as the first morning sample from all subjects after 
at least 6 hours fast prior )
. The consumption of the continental breakfast will occur within 30 
minutes prior to dosing and can occur as for Day s 2 -Days 8 before PK samples are collected. 
A light morning snack can be consumed in the mornings if dosing occurs after 11 am. 
Further, subjects will consume a snack within 30 minutes prior to their evening dosing.
The medication phase will be followed by  a 7 day  follow -up and wash -out period.
Table 4.1.4: 1 Composition of the standard continental breakfast as an example
Ingredients kcal
1bread roll 164
15 g butter 113
1 slice of Gouda cheese (approximately 40g) 146
1 slice of meat (approximately 20g) 33
1 cup of decaffeinated coffee or tea (without sugar) 2
Sum1458
1The total caloric content i s supplied approximately as following: approx. 88 kcal as protein, approx. 133kcal 
ascarbohydrate, andapprox. 237 kcal as fat.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 41of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Table 4.1.4: 2 BI 730357 , placebo and ciprofloxacin treatment s
Treat
ment
groupFasting 
condition 
predoseSubstance Pharm aceutical 
formUnit       
strengthNumber of units /dose   
volume per administrationTotal 
dose
A Fed1BI 730357 Film -coated 
tablet100 mg 4tablets QD 400mg
A Fed1Placebo Film -coated 
tablet-- 4tablets QD --
B Fed1Ciprofloxacin Film -coated 
tablet500 mg 1 tablet BID 1000m g
A Fed2BI 730357 Film -coated 
tablet100 mg 3tablets BID 600mg
A Fed1Placebo Film -coated 
tablet-- 3tablets BID --
1Drug administration after a standard continental breakfast 
2Drug administration after a standard continental breakfast  and evening snack
4.1.5 Blinding and procedures for unblinding
4.1.5.1 Blinding
At the trial site, access to the randomization schedule to treatment A or B will be restricted to 
pharmacists and dedicated staff members. 
The Treatment A parts (BI 400 mg QD/placebo and BI 300 mg BID/placebo) of thisstudy are
designed double -blind with regard to the subjects and the Investigators (as well as the 
research staff at the trial site) in order to eliminate observer or performance bias. This means 
avoiding s ystematic differences in assessments regarding the subj
A Fed1Placebo Film -coated 
tablet-- 4tablets QD --
ect’s treatment (active or placebo). 
Subjects, investigators, and every one involved in trial conduct or anal ysis or with an y other
interest in this double -blind part of the trialwill remain blinded with regard to the randomise d 
treatment assignments until after database lock.
The subjects, Investigators and study  site staff will not be aware of the treatment allocation 
(i.e., active vs placebo) from the time of randomization at 
Day 1 until database lock. 
The a ccess to the randomisation code will be kept restricted until its release for anal ysis.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 42of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019The randomisation codes will be provided to bioanaly tics prior to last patient completed to 
allow for the exclu sion from the anal yses ofpharmacokinetic ( PK) samples taken from 
placebo subjects . Bioanaly tics will not disclose the randomisation code or the results of their 
measurements until the trialis officially  unblinded.
In addition, the trial pharmacokineticist may receive the blinded (dummy  subject numbers 
will be used) results of the measurements to perform the preliminary  PK analy sis. 
Treatment B of thi s study will be conducted according to an open -label design however, the 
sub-investigator conducting photosensi tivity  assessments will be blinded. This means that the 
photosensitivity  assessments will be evaluated by persons who are independent of the other 
clinical trial procedures and not involved in other aspects of the trial . Treatment B will be 
administered on the same day s as Treatment A.
4.1.5.2 Unblinding and breaking the code
An e mergency  code break (envelope) for treatment A will be available to the investigator .
This code break may  only  be opened in an emergency  situation when the identity  of the trial
drug must be known to the investigator in order to provide appropriate medical treatment or 
otherwise assure safet y of trialparticipants. If the code break for a patient is opened, the 
sponsor must be informed immediately about the unblinding . The treatm ent allocation should 
not be disclosed to the sponsor unless this i s explicitly  requested. The reason for opening the 
code break must be documented on the envelope and/or appropriate CRF page.
Due to the requirements to report Suspected Unexpected Serious Adverse Reactions 
(SUSARs), it may  be necessary  for a representative from BI’sPharmacovigilance group to 
access the randomisation code for individual subjects during trialconduct. The access to the 
code will only  be given to authorised P harmacovigilance representatives for processing in the 
PV database s ystem and not be shared further. 
4.1.6 Packaging, labelling , and re -supply
The investigational medicinal product s will be provided by  BI. They  will be packaged and 
labelled in accordance with the principles of Good Manufacturing Practice (GMP).
For details of packaging and the description of the label, refer to the ISF.
4.1.7 Storage conditions
Drug supplies willbe kept in their original packaging and in a secure limited access storage 
area according to the recommended storage conditions on the medication label. A
temperature log must be maintained for documentation
If the storage conditions are found to be outside the specified range, the Clinical Research
Associate ( CRA ), as provided in the list of contacts, must be contact edimmediately .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 43of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20194.1.8 Drug accountability
The investigator or designee will receive the investigational drugs delivered by  the sponsor
when the following requirements are fulfilled:
Approval of the clinical trialprotocol by  the IRB / ethicsA vailability  of a signed and 
dated clinical 
trialcontract between the sponsor and the investigational site,
Approval/notification of the regulatory  authority , e.g. competent authorit y,
Availabilit y of the curriculum vitae of the Principal Investigator ,
Availability  of a signed and dated clinical trialprotocol ,
Availability  of the proof of a medical license for the P rincipal Investigator ,
Availability  of FDA Form 1572 .
Investigational drugs are not allowed to be used outside the context of this protocol. They  
must not be forwarded to other investigators or clinics. 
The investigator or designee must maintain records of the product’s delivery  to the trialsite, 
the inventory  at the site, the use 
by each subject , and the return to the sponsor orwarehouse / 
drug distribution centre or alternative disposal of unused products. If applicable, the sponsor 
or warehouse / drug distribution centre will maintain records of the disposal. 
These records will include dates, quantities, batch
/serial numbers, expiry  (‘use -by’) dates, 
and the unique code numbers assigned to the investigational medicinal product and trial
subjects . The investigator or designee will maintain records that document adequatel y that the 
subjects were provided the doses specified by  the Clinical Trial Protocol ( CTP)and reconcile 
all investigational medicinal product s received from the sponsor . At the time of return to the 
sponsor or appointed CRO, the investigator or designee must verify  that all unused or 
partially  used drug supplies have been returned and that no remaining supplies are in the 
investigator ’s possession.
4.2 O THER TREATMENTS , EMERGENCY PROCEDURES , 
RESTRICTIONS
4.2.1 Other treatments and 
emergency procedures
There are no special emergency  procedures to be followed.
4.2.2 Restrictions
4.2.2.1 Restrictions regarding concomitant treatment
In principle, no concomitant treatments are allowed. 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 44of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019In case of AEs in need of treatment, s ymptomatic therapy  according to investigator judgment 
will be permitted. All concomitant and/or rescue therapies will be recorded on the appropriate 
pages of the eCRF. 
In addition, a list of medications with potential drug- drug interactions, transport and 
phototoxic interactions and/or references can be found in the Appendix 10.1 . For further 
guidance investigators are referred to the actual Investigator´s Broch ure or may  contact the 
sponsor.
4.2.2.2 Restrictions on diet and life sty le
Subjec ts must be fasted for at least 6 hours prior to collection of the safet y laboratory  
samples .
Foods which are known strong or moderate inhibitors of CYP 3A ( e.g., fruit juices from star 
fruit, paw paw, grapefruit) should be avoided during the stud y participation.
The use of tanning beds isnot allowed during the study .
Throughout their participation in the study , participants should avoid direct sunlight. When 
exposed to sunlight study participants should protect skin areas not covered by  clothes b y 
using sun -protection creams and lip balms with sun pr otection factor 30 or higher with 
protection against UV -A and UV -B. Additionally , subjects should wear sunglasses when 
exposed to direct sun or other sources of UV -light.
These protection measures must be applied until the EOT visit.
4.2.2.3 Contraception require ments
Women of childbearing potential must use highly effective methods of birth control per ICH 
M3(R2) that result in a low failure rate of less than 1% per year when used consistently  and 
correctly . A list of contraception methods meeting these criteria is provided in the patient
information.
4.3 T REATMENT COMPLIANCE
Compliance will be assured by  administration of all trial medication in the study  centre under 
supervision of the investigating ph ysician or a designee. The measured plasma concentrations 
will provide additional confirmation of compliance.
Subjects who are non -compliant (for instance, who do not appear for scheduled visits or 
violate trial restrictions) may  be removed from the trial and the CRF will be completed 
accordingl y
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 45of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20195. ASSESSMENT S
5.1 A SSESSMEN T OF PHOTOSENSITIVITY
Two Multiport Solar Simulator model s 601 (  will 
be used for irradiation (150 W or 300 W xenon arc lamp, dichroic mirror, and equipped with 
filters to produce UVA or UVA+B (290 -400nm) outputs) . This light source isequipped with 
6 liquid light wave guides e xtending out of the case and an automated shutter device allo wing 
for precise delivery  of UV light doses per individual wave guide . Actual irradiation values 
delivered by the individual light guides will berecorded throu ghout the study  using a 
PMA2100 Radiometer ( ) equipped with a 
PMA2113 UVA sensor (physical irradiation in the range of 320 to 400 nm) and with a 
PMA2103 UVB sensor (biologicall y weighted, er ythemal effective irradiation).
A series of unprotected naive skin test sites on the back will be irradiated with the following 
three different conditions, meant to simulate three different environmental sunlight exposure 
scenarios /conditions:
1. Conditio n 1: Full range solar UVB/UVA (290 to 400 nm, UBV content ~10%), simulating 
midday  summer outdoor sun exposure (assessed in µw/cm2).
2. Condition 2: UVA only (320 to 400 nm, UVB content <0.03%), simulating indoor 
exposure behind window glass with a secon dary assessment of erythema and local skin 
reactions at 25 J cm−2(assessed in mw/cm2).
Subjects will be exposed to a series of 6 graded full range solar UVB/UVA exposures 
(Condition 1) and UVA only exposures (Condition 2),each 25% greater than the previous 
dose. Following irradiation, skin sites will be evaluated for erythema or skin darkening (for 
UVA-onl y exposure in the absence of additional, drug -induced phototoxicity ). 
TheMED will be defined as the lowest dose that produced uniform redness (condition 1) or 
darkening (condition 2) (assessed in joules (J) for UVA and millijoules (mJ) for UVB/UVA) . 
An approximate MED preliminary will be irradiated on day -3 and will be evaluated 10 min, 1 h 
and 24 h post irradiation. The initial MED preliminary will be used to fine-tune the irradiation 
range for the determination of a precise MED baseline on day -2.The MED baseline irradiation will 
occur on day-2 and will be evaluated 10 min, 1 h and 24 h post irradiation. 
Outpatient pre -treatment photosensitivity  testing will occur prior to the dose administration 
on day  1 as follows:
Day -3 
Irradiate Preliminary  MEDs (Condition 1 and Condition 2) followed by  MED 
assessments at 10 ±2 minutes, 1 hour ±5 minutes

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 46of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Day -2
Assessment of Preliminary  MEDs at at 24 hours ±10 minutes post irradiation.  
Irradiate Baseline MEDs (Condition 1 and Condition 2 , +/-30 min to planned time ) 
followed b y MED assessments at 10 ±2 minutes, 1 hour ±5 minutes   
Day -1
Assessment of Baseline MEDs (Condition 1 and Condition 2) at 24 hour±10 minutes 
post irradiation.  
Irradiate Baseline Condition 3 (+/-30 min to planned time) followed b y assessments 
at 10 ±2 minutes and 1
-hour ±5 minutes. 
Day 1
Post-treatment photosensitivity  testing will occur 2 hours (±10 minutes) after final dose 
administratio
non day  8, with the sa me irradiation conditions as on day -1as follows:
Day 8
Irradiate MEDs (Condition 1 and Condition 2) followed by  MED assessments at 10 
±2 minutes, 1 hour ±5 minutes
Irradiate Condition 3 followed b y assessments at 10 ±2 minutes, 1 hour ±5 minutes
Day 9
Assessment of MEDs (Condition 1 and Condition 2) at 24 hour±10 minutes post 
irradiation.  
Assessment of Condition 3 at 24 hours post hours ±10 minutes post irradiation.  
The photosensitivity  index (PI) will be calculated as the ratio of the MED baseline versus 
MED on drug for irradiation Conditions 1 and Conditions 2.
Additionally , inflammatory  responses (ery thema and local skin reactions) and superficial skin 
eff
ects will be scored (see scales in Table below) under all conditions at baseline (10 min, 1 h 
and 24 h post -irradiation) , and post -treatment day  8 (10 min, 1 h, 24 h, 48 h and 72 h post -
irradiation).

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 47of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Inflammatory  skin reactions will be scored according to:
Skin Reaction Grading Scales
Erythema Grading Scale Local Skin Reaction Superficial Effects Grading
0No evidence of ery thema EEdema -swelling, spongy
feeling when palpatedgGlazing
1Very  slight ery thema
(barel y perceptible)PPapule -red, solid,
elevationy Peeling
2 Well defined ery thema VVesicle -small elevation
containing fluidcScab, dried film of serous
exudate of vesicular or
bullous reaction
3Moderate to severe     
erythemaBBullous reaction -fluid
filled lesion (blister)dHyperpigmentation
(reddish- brown
discoloration of test -site)
4Severe ery thema (beet
   redness)SSpreading -evidence of
the reaction bey ond the
irradiated areahHypopigmentation (loss
of visible pigmentation at
test site)
WWeeping -result of a
Vesicular or bullous reaction 
serious exudatefFissuring -grooves in the
superficial lay ers of the skin
I   Induration -solid, elevated,
hardened, thickened skin
-Response occurs ≤25% of
test site
5.2 A SSESSMENT OFSAFETY
5.2.1 Physical examination
A complete ph ysical examination will be performed at the time points specified in the 
flowchart . It includes ata minimum general appearance, skin, head, neck, throat, ly mph 
nodes, lungs, cardiovascular and neurological system s, abdomen, and extremities . 
Measurement sof height and body  weight will be performed at screening only .
The results must be included in the source documents available at the site. 
5.2.2 Vital s igns
Vital signs will be evaluated at the t ime points specified in the flowchart, prior to blood 
sampling.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 48of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019This includes systolic and diastolic blood pressure and pulse rate (electronically  or by 
palpation count for 1 minute ) in a supine position after 5 minutes of rest. The results must be 
include d in the source documents available at the site.
5.2.3 S afety laboratory parameters
Safety  laboratory  parameters to be assessed are listed in Table 5.2.3: 1 below .For the 
sampling time points please see the flowchart .Additional testing for infectious deseases can 
be added at an y timepont during the stud y, as requested by the authorit y, or judged b y the 
investigator.
All analy ses will be performed by  a sitelocal laboratory , the respective reference ranges will 
be provided in the ISF. 
Subjects have to be fasted for at least 6hours prior to the blood sampling for the safet y 
laboratory . 
The labora tory will send reports to the investigator . It is the responsibility  of the investigato r
to evaluate the laboratory reports. Clinically  relevant abnormal findings as judged b y the 
investigator will be reported as adverse events (please refer to section 5.2.6).
In case the criteria for hepatic injury  are fulfilled, a number of additional measures will be 
performed (
please seesection 5.2.6.1 andthe DILI Checklist provided in the ISF.The amount 
of blood taken from the patient concerned will be increased due to this additional sampling.
The clinical local laboratory  will transfer the results of the anal ysis to the sponsor / sponsor 
representative .
Table 5.2.3: 1 Safet y laboratory
Functional lab group Test name A1B2C3
Haem atology Haem atocrit
Haem oglobin
Red blood cells (RBC)
White blood cells (WBC)
Platelet count
MCV
MCH
MCHC
RDWX
X
X
X
X
X
X
X
XX
X
X
X
X
X
X
X
XX
X
X
X
X
X
X
X
X
Automatic WBC 
differential 
(relative and absolute)Neutrophil es total
Lymphocytes total
Eosinophil es 
Basophil es 
Monocytes X
X
X
X
XX
X
X
X
XX
X
X
X
X
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 49of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Lymphocytes X X X
Manual differential WBC 
(if automatic differential 
WBC is abnormal)Polymorphnuclear neutrophils (segs), band 
neutrophils (stabs), eosinophils, basophils, 
monocytes, lymphocytes 
Coagulation Activated partial thromboplastin time (aPTT)
Prothrombin Time ( PT)
INRX
X
X
Functional lab group Test name 
Enzymes Aspartate aminotransferase (AST) 
Alanine aminotransferase (ALT) 
Alkaline phosphatase (AP)
Gammaglutamyl transferase (GGT)  
Creatine kinase (CK)
Lipase
AmylaseX
X
X
X
X
X
XX
X
X
XX
X
X
X
X
X
Substrates Glucose
Creatinine
Urea Nitrogen
Uric Acid
Total bilirubin 
Direct bilirubin
Total protein
Albumin
Globulin
Albumin/Globulin ratio
C-Reactive Protein (CRP) 
Total cholesterol X
X
X
X
X
X
X
X
X
X
X
XX
X
X
X
X
XX
X
X
X
X
X
Electrolytes Calcium
Sodium
Potassium
Chloride
PhosphateX
X
X
X
XX
X
X
X
X
Serum Pregnancy test 
(only for female subject s 
of childbearing potential) 
at screening , day  -1and if 
urine pregnancy test is 
positiveHuman Serum Chorionic Gonadotropin X X4
Urinalysis (Stix) Urine nitrite
Urine protein
Urine glucose
Urine ketone
Urine bilirubin
Urine Blood
Urine leukocyte esterase
Urine pH
Specific gravityX
X
X
X
X
X
X
X
XX
X
X
X
X
X
X
X
X
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 50of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20191 A: parameters to be determined at screening examination
2 B: parameters to be determined on Day s 1 and 8
3 C: parameters to be determined at end of trial examination
4 Day -1 only
Manual differential white blood cell count or urine sediment examinations will only  be 
performed if there is an abnormality  in the automatic blood cell count or in the urinaly sis, 
respectivel y.
The tests listed in Table 5.2.3:
1andTable 5.2.3: 2 may be repeated as required. The results 
of the Exclusionary  laboratory tests listed below will not be entered in the CRF/database and 
will not be reported in the CTR. Except for drug screening, it is planned to perform these 
tests during screening only . Drug screening will be performed at screening and prior to 
administration of tr ial medication on Day -
1(for time points refer to Flow Chart ).Urine sediment 
(microscopic examination 
if erythrocytes, leukocytes 
nitrite or protein are 
abnormal in urine)Only positive findings will be reported (e.g. 
presence of s ediment bacteria, c astsin sedim ent, 
squamous epithelial cells, erythrocytes,
leukocytes )
Urine Pregnancy test (only 
for female subject s of 
childbearing potential) at 
EoTHuman Chorionic Gonadotropin in the urine X
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 51of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Table 5.2.3: 2 Exclusionary  laboratory  tests
Functional lab group Test name 
Drug screening (urine)Amphetamine
Barbiturates
Buprenorphine
Benzodiazepine
Cocaine 
Methadone methabolite
Methadone
Methamphetamine
Ecstasy
Morphine
Opiates 
Oxycodone
Phencyclidine
Tricyclic antidepressants
Marijuana
Infectious serology (blood)1Hepatitis B surface antigen (qualitative)
Hepatitis B core antibody (qualitative)
Hepatitis C antibodies (qualitative)
HIV-1 and HIV -2 antibody (qualitative)
IGRA -T (e.g. QuantiFERON®-TB Gold IT Test)
1 Additional testing for infectious deseases can be added as requared
To encourage compliance with alcoholic restrictions, a breath alcohol test will be performed 
prior to admission on Day -1, and may  be repeated at any  time during the study  at the 
discretion of an Investigator or designee. The results will not be included in the CTR.
Laboratory  data will be transmitted electronicall y from the laboratory  to the trial site.
5.2.4 Electrocardiogram
The 12
-lead ECGs must be administered by  a qualified technologist and results will be 
recorded as scheduled in the flowchart. The investigator or a designee will evaluate whether 
the ECG is normal or abnorma l and assess clinical relevance . ECGs may  be repeated for 
quality  reasons and a repeated recording used for anal ysis. 
Additional ECGs may  be recorded for safet y reasons. Dated and signed printouts of ECG 
with findings should be documented in subject ’s medical record.
Clinically  relevant abnormal findings will be reported either as baseline condition (if 
identified at the screening visit) or otherwise as AEs and will be followed up and/or treated as 
medically  appropriate.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 52of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20195.2.5 O ther safety parameters
Not applicable.
5.2.6 Assessment of adverse events
5.2.6.1 Definitions of AEs 
5.2.6.1.1 Adverse event
An AE is defined as a ny untoward medical occurrence in a patient or clinical investigation 
subject administered a medicinal product and which does not necessaril y have to have a 
causal relationship with this treatment.
An AE can therefore be any  unfavourable and unintended sign (including an abnormal 
laboratory  finding), s ymptom, or disease temporally  associated with the use of a medicinal 
product, whether or not considered related to the medicinal product.
The followin g should also be recorded as an AE in the CRF andBI SAE form (if applicable):
Worsening of the underly ing disease or of other pre -existing conditions 
Changes in vital signs, ECG, phy sical examination and laboratory  test results, if they  
are judged clinically  relevant by  the 
investigator .
If such abnormalities already  exist prior to trial inclusion ,they will be considered as baseline 
conditions and should be collected in the eCRF .
5.2.6.1.2 Serious adverse event
A serious adverse event (SAE) is defined as an y AE ,which fulfils at least one of the 
following criteria :
-results in death,
-is life -threatening, which refers to an event in which the patient was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might have 
caused death if more severe
,
-requires inpatient hospitalisation orprolongation of existing hospitalisation
- results in persistent or signif icant disability  or incapacity ,
-is a c ongenital anomal y /birth defect,
-is deemed serious for any other reason if it is an important medical event when based 
on appropriate medical judg ement which may  jeopard isethe patient and may  require 
medical or surgical intervention to prevent one of the other outcomes listed in the 
above definitions. Examples of such events are intensive treatment in an emergency  
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 53of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalisati on or development of dependency  or abuse. 
5.2.6.1.3 AEs considered “Alway s Serious”
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of AEs, which by  their nature, can alway s be 
considered to be “serious” even though they  may  not have met the criteria of an SAE as 
defined above.
The latest list of “Alway s Serious AEs” can be found in the eDC sy stem. A copy  of the latest 
list of “Alway s Serious AEs” will be provided upon request. T hese events should alway s be 
reported as SAEs as described in section 5.2.6.2.
Cancers of new histology and exacerbations of existing cancer must be classified as a serious 
event regardless of the time since discontinuation of the drug and must be reported as 
described in 5.2.6.2, subsections “AE Collection ”and“AE reporting to sponsor and 
timelines ”.
5.2.6.1.4 Adverse events of special interest
The term adverse events of special inte rest ( AESI )relates to an y specific AE that has been 
identified at the project level as being of particular concern for prospective safet y monitoring 
and safet y assessment within this trial, e.g. the potential for AEs based on knowledge from 
other compounds in the same class. AESI sneed to be reported to the sponsor ’s 
Pharmacovigilance Department within the same timeframe that applies to SAE s, please see 
section 5.2.6.2.2.
The following are considered as AESIs:
Hepatic injury
A hepatic injury  is defined by  the following alterations of hepatic laboratory  parameters: 
an elevation of AST (A spartate Aminotransferase ) and/or ALT (Alanine 
Aminotransferase) ≥3 fold ULN combined with an elevation of total bilirubin ≥2 fold 
ULN measured in the same blood draw sample, or
Aminotransferase (ALT, and/or AST) elevations ≥10 fold ULN .
These lab findings constit ute a hepatic injury  alert and the subjects showing these lab 
abnormalities need to be followed up according to the “DILI checklist” provided in the I SF.
In case of clinical s ymptoms of hepatic injury  (icterus, unexplained encephalopathy , 
unexplained coag ulopathy , right upper quadrant abdominal pain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are 
analysed, if necessary  in an unscheduled blood test. Should the results meet the criteria of 
hepatic injury  alert, the procedures described in the DILI checklist should be followed .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 54of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Severe infections (according to RCTC grading)
Opportunistic and my cobacterium tuberculosis infections
These include pneumocystis jirovecii, BK virus disease including PVAN, CMV, post -
transplant ly mphoproliferative disorder (EBV), progressive multifocal leucoencephalopathy , 
bartonellosis (disseminated only ), blastomy cosis, toxoplasmosis, coccidioidomy cosis, 
histoplasmosis, aspergillosis (invasive only ), candidiasis (invasive or pharyngeal), 
cryptococcosis, other invasive fungi (mucorm ycosis (zy gomycosis, rhizopus, mucor, 
lichtheimia), scedosporium/pseudallescheria bo ydii, fusarium), legionellosis, listeria 
monocy togenes (invasive only ), tuberculosis, nocardiosis , non- tuberculous my cobacterium, 
salmonellosis (invasive only ), HBV reactivation, herpes simplex (invasive only ), herpes 
zoster, strongy loides (h yperinfection syndrome and disseminated forms only), 
paracoccidioides, penicillium marneffei, sporothrix schenc kii, cry ptosporidium species 
(chronic onl y), microsporidiosis, leishmaniasis (visceral onl y), tr ypanosoma cruzi infection 
(Chagas’ disease) (disseminated only ), campy lobacteriosis (invasive onl y),  shigellosis 
(invasive only ), vibriosis (invasive due to vi brio vulnificus), HCV progression.
5.2.6.1.5 Intensit y (severit y) of AEs
The intensity  (severit y) of the AE should be judged based on the following:
Mild: Awareness of sign(s) or sy mptom(s) that is/are easily  tolerated .
Moderate: Sufficient 
discomfort to cause interference with usual activity .
Severe: Incapacitating or causing inability  to work or to perform usual activities.
5.2.6.1.6 Causal relationship of AEs
Medical judg ement should be used to determine whether there is a reasonable possibility of a 
causal relationship between the adverse event and the given stud y treatment , considering all 
relevant factors, including pattern of reaction, temporal relationship, de -challenge or re -
challenge, confounding factors such as concomitant medication, concomitant diseases and 
relevant history . 
Arguments that may  suggest that there is a reasonable possibility  of a causal relationship 
could be :
The event is consistent with the known pharmacology  of the drug .
The event is known to be caused b y or attributed to the drug class.
A plausible time to onset of the event relative to the time of drug exposure.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 55of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Evidence that the event is reproducible when the drug is re- introduced.
No medicall y sound alternative aetiologies that could explain the event (e.g. pre -
existing or concomitant di seases, or co -medications).
The event is t ypicall y drug -related and infrequent in the general population not 
exposed to drugs (e.g. Stevens- Johnson sy ndrome).
An indication of dose -response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is reduced).
Arguments that may  suggest that there is no reasonable possibility  of a causal relationship 
could be:
No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre -treatment cases, diagnosis of cancer or chronic disease within days /weeks 
of drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned) .
Continuation of the event despite the withdrawal of the medication, taking into 
account the pharmacological pr operties of the compound (e.g. after 5 half- lives).
Of note, this criterion may not be applicable to events whose time course is prolonged 
despite removing the original trigger.
Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underl ying diseases appear to provide a more likely  
explanation for the observed event than the drug concerned).
Disappearance of the event even though the trialdrug treatment continues or remains 
unchanged.
5.2.6.2 Adverse event collection and reporting
5.2.6.2.1 AE Collection
The investigator shall maintain and keep detailed records of all AEs in the subject files.
The following must be collected and documented on the appropriate CRF(s) by  the 
investigator :
•From signing the in formed consent onwards until the individual subject ’send of trial(the 
End of Trial (EoTrial) visit) : 
all AEs (serious and non -serious) and all AESIs.
•After the individual subject ’s end of trial: 
the investigator does not need to activel y monitor the subject for new AEs but should 
only report an y occurrence of cancer and trial treatment related SAEs and trial treatment 
related AESIs of which the investigator may become aware of by any means of 
communication, e.g. phone call. Those AEs should be reported on the BI SAE form ( see 
section 5.2.6.2.2), but not onthe CRF.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 56of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20195.2.6.2.2 AE reporting to the sponsor and timelines
The investigator must report SAEs, AESI s, and non -serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately  (within 24 hours ) t o the 
sponsor’s unique entry  point (country  specific contact details will be provided in the I SF). 
The same timeline applies if follow-up information becomes available. In specific occasions ,
the investigator could inform the s ponsor upfront via telephone. This d oes not replace the 
requirement to complete and fax the BI SAE form.
With receipt of an y further information to these events, a follow -up SAE form has to be 
provided. For follow -up information the same rules and timeline apply  as for initial 
information. All(S)AEs, including those persisting after individual patient ’s end of trial must 
be followed up until they have resolved, have been assessed as “chronic” or “stable” , or no 
further information can be obtained.
5.2.6.2.3 Pregnancy
In rare cases, pregnancy  might o ccur in a clinical trial. Once a subject has been enrolled in 
the clinical trialand has taken trialmedication, the investigator must report any  drug 
exposure during pregnancy  in a trialparticipant immediately  (within 24 hours) by  means of 
Part A of the Pregnancy  Monitoring Form to the 
sponsor ’s unique entry  point.
The outcome of the pregnancy  associated with the drug exposure during pregnancy  must be 
followed up and reported to the sponsor’s unique entry  point on the Pregnancy  Monitoring 
Form for Clinical Studies (Part B).
The I SF will contain the Pregnancy  Monitoring Form for Clinical Studies (Part A and B) .
As pregnancy  itself is not to be reported as an AE, in the absence of an accompany ing SAE 
and/or AESI, onl y the Pregnancy Monitoring Form for Clinical Studies and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pregn ancy  an SAE 
form must be completed in addition.
5.2.6.2.4 Exemptions to SAE r eporting
Not applicable
5.3 DRUG CONCENTRATION M EASUREMENTS AND 
PHARMACOKINETICS
5.3.1 Assessment of p harmacokinetic s
PK parameters for exposure and disposition will be calculated. S tandard multiple dose PK 
parameters will be calculated and further specified in the TSAP.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 57of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019The relationshi p between BI 730357 plasma concentrations , photosensitivity endpoints, and 
AEs may  be assessed.
5.3.2 Methods of sample collection
For quantification of BI730357) plasma concentrations, 4mL of blood will be taken from an 
antecubital or forearm vein into a K -3EDTA (tripotassium ethy lenediaminetetraacetic acid) -
anticoagulant blood drawing tube at the times indicated in the Flow Chart andin Appendix 
10.2. Blood will be withdrawn b y means of either an indwelling venous catheter or b y 
venepuncture with a metal needle.
After blood draw all samples have to be protected against direct sunlight to avoid conversion 
of pres ent metabolite into parent drug BI 730357. The EDTA -anticoagulated blood samples 
will be centrifuged for about 10 min utesat app. 1000 to 2000 g at about 2 to 4 °C. Two 
plasma aliquots will be obtained and stored in poly propy lene tubes. The first aliquot sh ould 
contain at least 0.5 mL plasma the second aliquot should contain the remaining plasma . The 
process from blood collection until transfer of plasma aliquots into the freezer should be 
completed within 120 minutes, with interim storage at room temperature . For each aliquot the 
time when the sample was placed in the freezer will be documented. Until transfer on dry  ice 
to the anal ytical laboratory , the aliquots will be stored upright at about - 20°C or below at the 
trial site. The second aliquot will be tra nsferred to the anal ytical laboratory  after the 
bioanaly st has acknowledged safe arrival of the first aliquot. At the anal ytical laboratory  the 
plasma samples will be stored at about -20°C or below until analy sis.
Quantification of ciprofloxacin plasma concentrations will not be performed.
At a minimum, the sample tube labels should list the following information: BI trial number, 
subject number, visit, and planned sampling time. Further information, such as matrix and 
analyte, may  also be provided. 
After completion of the trial, the plasma samples may  be used for further methodological 
investigations, e.g. ,for stability  testing, assessment of metabolites. However, only  data 
related to the anal yte and/or its metabolite(s) will be generated b y these addi tional 
investigations. The stud y samples will be discarded after completion of the additional 
investigations, but not later than 5 years after the final study  report has been signed.
The results of an y further investigations are not planned to be part of the CTR but can be
included into the CTR if necessary .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 58of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20195.4 ASSESSMENT OF BIOMAR KER(S)
Not applicable.
5.5 BIOBANKING
Not applicable.
5.6 OTHER ASSESSMENTS
Not applicable.
5.7 APPROPRIATENESS OF M EASUREMENTS
All measurements performed during this trial, except from the skin t ypeand photosensitivity  
assessments ,
are standard measurements in clinical trials and will be performed in order to 
monitor safety  aspects in an appropriate way .
UV photo safet y testing (conduct and interpretation of ultraviolet (UV) irradiation) is well 
established at the clinical site and will be performed by clinical, medical and technical staff 
which is appropriatel y trained and familiar with the methods and assessments required in this 
trail.
The number of investigator designees performing skin evaluations is kept as small as possible 
to ensure consistency . All dermatological assessments will be performed in a room with 
standardized environmental conditions (e.g., light conditions, temperature).
Therefore, the appropriateness of all measurements applied in this trial is given.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 59of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20196. INVESTIGATIONAL PLAN
6.1 VISIT SCHEDULE
All subjects have to adhere to the visit schedule as specified in theFlow charts . Each visit 
date is to be counted from Day  1. 
Additional visits for the purpose of re- testing of laboratory  parameters or AE monitoring may  
be included as deemed necessary  by the investigator.
Study  procedures to be performed at each visit are listed in the Flow Charts and the 
respective protocol sections. Additional details on procedures at selected visits are provided 
below.
Measurement of vital signs should precede blood sampling. All blood samplings on all visits 
which are not intensive PK
-days should occur prior to the intake of medication.
For detailed description of the trial procedures, please refer to the Flow Charts .
6.2 DETAILS OF TRIAL PROCEDURES AT SELECT ED VISITS
6.2.1 Screening and run -in period(s)
Screening Period
After having been informed about the trial, all subje cts will give their written informed 
consent in accordance with GCP and local legislation prior to enrolment in the study . 
The screening should take place no more than 28days before Day  1.
At the screening visit, the medical examination will include docu mentation of subject 
information, informed consent, demographics including height and bod y weight, smoking 
and alcohol history , relevant medical history  and concomitant therap y, review of inclusion 
and exclusion criteria, review of vital signs (BP, PR , and temperature ), 12-lead ECG, 
laboratory  tests
, and a phy sical examination. Subjects who have laboratory test value (e.g. ,
platelet count) clinicall y outside acceptable ranges, may have the test repeated once to 
determine eligibility ; however, the result of re -assessment must be available prior to 
randomisation (Day  1).
After all general screening clinical assessments were performed, onl y subjects who meet
eligibility  criteria will undergo UV irradiation and pr eliminary  photosafet y testing will be 
performed.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 60of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019The preliminary photosensitivity  examination will be performed no later than Day -3, 
followed b y the base line irradiation and photosensitivity  assesments stariting on day  -2.
Baseline Conditions
Subjects eligible forthe study participation will be admitted to the clinical site on day -1, and
check of In/Exclusion criteria as well as Base- line photosensitivity  assessment will be 
performed .
If possible, spare subjects will be provided for each grou p to guarantee the start of a complete 
group. The spare subjects will participate in all trialactivit ies up to Day  1, i.e. on Day  -1 they  
will be admitted to the clinic and all examinations, which have been scheduled up to drug 
administration on Day  1 wil l be performed. T he spare subjects from one group will be given 
the option to participate in the next planned group.
6.2.2 Treatment period(s)
Treatment A
Subjects will be randomized in the morning on Day 1 and receive 400mg of BI 730357 or 
placebo once daily over 8days, or 3 00mg of BI 730357 or placebo twice daily  12 hours apart 
over 8 day s with the single dose on day  8,inorder to reach pharmacokinetic steady  state;  
UVB/UVA irradiation will occur  2 hours after the last dose of either IP or placebo, and 
photosensitivity  assessments (determination of MED On drugand evaluation of erythema/local 
skin reactions) will be performed at 10 (+/
-2) minutes, and 1(+/- 5 min) , 24(+/ - 10 min)
Treatment B
Subjects will receive their first dose of 500 mg ciprofloxacin on the morning of Day 3. 
Twelve (12) hours later, subjects received their second dose of 500 mg ciprofloxacin. 
Subjects continued a twice -daily dosing regimen through to the morning of Day 8to ensure 
they have reached pharmacokinetic stead y state
UVB/UVA irradiation will occur 2 hours after the last dose of Ciprofloxacin, and 
photosensitivity  assessments (determination of MED On drugand evaluation of erythema/local 
skin reactions) w ere performed at 10 (+/
-2) minutes, and 1 (+/-5 min) , 24(+/-10 min) , 
For details on time points for all other trial procedures, refer to the Flow Chart . AEs and 
concomitant therap y will be assessed continuously from screening until the end of trial 
examination.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 61of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20196.2.3 Follow -upperiod and trialcompletion
End of Trial
Subjects who completed the treatment according to the protocol, as well as subjects who 
discontinued treatment before the end of the planned treatment period should undergo the end 
of trial visit 7daysafter last intake of the study  medication.
For AE assessment, laboratory  tests, recording of ECG and vital signs, and phy sical 
examination during the e nd of trial refer to the Flow charts .
All abnormal values (including laboratory  parameters) that are judged clinically  relevant by  
the Investigator will be monitored using the appropriate tests until a return to a medicall y 
accep table level is achieved. (S)AEs persisting after subject’s end of trial must be followed 
up until they  have resolved, have been sufficiently  characterized, or no further information 
can be obtained . 
The end of the trial as a whole is defined b y the ‘last regular visit completed by  last subject’ 
or ‘end date of the last open AE’ or ‘date of the last follow -up test’ or ‘date of an AE has 
been decided as sufficiently  followed- up’, whichever is latest.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 62of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20197. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
Theobjective of this trial isto investigate the photosensitivity  under three distict exposure 
conditions of BI 730357 following 8 day s of administra tion(i.e. stead y state) on the basis of 
the primary  and secondary  endpoints
.  The trial is designed to allow comparisons between BI 
730357 and placebo as w ell as BI 730357 and a positive control (ciprofloxacin ).  These 
comparisons will be evaluated statistically  by use of a mixed model for repeated measures.
Each double blind randomization group (Part A: BI 730
357 400 QD/placebo and BI 730357 
300 BID/placebo) will be anal ysed separatel y for the assessment of photosensitivity .
7.1 NULL AND ALTERNATIVE HYPOTHESES
BI 730357 vs placebo
The assessm ent for absence of photosensitivity  will be based upon the differences in mean 
photosensitivity  index (PI)between BI 730357 and placebo two -sided 90% confidence 
intervals (C Is) for the differences in the photosensitivity  index ( Section 7.2.2) be tween BI 
730357 and placebo using an acceptance range of -0.4 to 0.4.  This method is equivalent to 
the two- sided t -test procedure, each at the 5% significance level.
The following comparisons will be performed:
BI 730357 400 mg QD vs placebo 400 mg QD
BI 730357 300 mg BID vs placebo 300 mg BID
The following hy pothes esaretested: 
Null hy pothesis H 0(Photosensitive ): µBI-µpbo≤ -ẟorµBI-µpbo≥ ẟ
Where µBIand µpboare the means of the endpoint for BI 730357 and placebo, respectivel y, 
and δis the limit that defines the acceptance range for photosensitivity  equivalence .
Alternative h ypothesis H a(Absence of photsensitivity ): -
ẟ <µBI-µpbo< ẟ
In this trial, the equivalence limit δis 0.4 which is consistent with historical criteria used for 
positive photo sensitivity  for a drug (R19-3037).
The rejection of the null hy pothes isat the =0.05 level is equivalent to the inclusion of the 
90% confidence interval for µBI-µpboin the acceptance range ( -δ, δ).
Although there are multiple endpoints where the photosensitivity  index will be statistically  
compared , an alpha adjustment is not needed because it is required that all endpoints meet the 
equivalence criterion as described above simultaneously .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 63of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019BI 730357 vs ciprofloxacin, Placebo vs ciprofloxacin
Comparisons between the mean PIbetween BI 730357 and ciprofloxacin as well as between 
placebo and ciprofloxacin at the different timepoints under con ditions 1 and 2 will be 
performed.
The planned comparisons are:
BI 730357 400 mg QD vs ciprofloxicin
BI 73 0357 300 mg BID vs ciprofloxicin
Placebo for 400 mg QD vs ciprofloxicin
Placebo for 300 mg BID vs ciprofloxicin
At each timepoint the null hy pothesis will be that there is no difference in the mean PI of BI 
730357 compared to ciprofloxacin:
Null hy pothesis H 0: µBI/pbo-µcipro= 0
Where µBI/pboand µciproare the means of the endpoint for BI 730357 or placebo and 
ciprofloxicin, respectively
The alternative hy pothesis will be that the means are not equal:
Alternative h ypothesis H a:µBI/pbo-µcipro≠0
A significant finding of increased photosensitivity of ciprofloxacin compared to BI 730357 
and to placebo at the p<0.05 level will be supportive in concluding that the trial was 
appropriatel y designed to test the photosensitivity  of BI 730357.
7.2 PLANNED ANALYSES
7.2.1 G eneral considerations
Analy sis sets
Statistical analy ses will be based on the following anal ysis sets:
Treated set (TS): The treated set includes all subjects who were randomized and 
treated with at least one dose of study  drug. The treat ed set will be used for safet y 
analyses.
Full anal ysis set (FAS): This set includes all subjects in the t reated set (TS) who 
provide at least one photosensitivity  endpoint that was defined as primary  or 
secondary  and was not excluded due to a protocol devi ation relevant to the evaluation
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 64of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019of photosensitivity . Descriptive and model based anal yses of photosensitivity  
endpoints will be based on the FAS .
Additional analy sis sets , refinements of the above definitions, orother relevant details may be 
specified in the TSAP.   The implications that patients with important protocol deviations 
(including receiving incorrect medication) might have on the anal ysis will be discussed at the 
report planning meeting(s) and decisions will be documented in the decision log.
7.2.2 Primary endpoint 
analyses
Photosensitivity  index (PI)
The photosensitivity  index (PI) under conditions 1 and 2 is the measurement used for the 
primary  endpoints.  It is defined as the ratio of the precise MED baseline to the MED on-drug(see 
Section 5.1) at each respective post- irradiation timepoint.  Therefore, there will be MED
baseline at 10 min, 1h, and 24h that will be used for the respective PI calculations , PI 10min, PI 1h, 
andPI24h.  For example, the PI 1hwill be the precise MED baseline /MED on-drugwhere each MED 
was measured at the 1 hour post -irradiation time point.   The two primary  endpoints are PI at 
24 hours under conditions 1 and 2.
A mixed model for repeated measures on P I values will be utilized for the analy sis.  The 
model will include treatment (BI 730357, Placebo, ciprofloxacin), time (10min, 1h, 24h, 48h, 
and 72h), and treatment- time interaction as fixed effects and subject as a random effect.  
Adjusted means and differences in PI and90% C Isfor the 2 contrast sof interest (i.e . BI 
703357 – placebo at 24h) will be calculated from the model.
The anal ysis will be carried out separatel y for condition 1 and condition 2.
Additional details , including the full specification of th e FAS (if needed) and the handling of 
patients who may  not have post -baseline data, will be included in the TSAP.
7.2.3 Secondary endpoint analyses
The secondary  endpoints for differences in PI at 10min and 1h 
under conditions 1 and 2 will 
be calculated from the same model as described for the primary  anal yses.
Additionally  percent change from ba seline in MED at 10min, 1h, and 24h will be calculated 
as ((MED on-drug-MED baseline )/ MED baseline )*100 at each timepoint and the same model using 
described in the primary anal ysis will be used in the anal yses of these endpoints.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 65of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20197.2.5 Safety analyses
Adverse events will be coded using the Medical Dictionary  for Drug Regulatory  Activities
(MedDRA). Standard BI summary  tables and listings will be produced. All adverse events 
with an onset between start of treatment and end of the REP, a period of 7 daysafter the last 
dose of trialmedication ,willbe assigned to the on-treatment period for evaluation.
The safet y analysis will be done by  ‘random isedtreatment’.
All treated subjects will be included in the safet y analysis. In general, safety  analy ses will be 
descriptive in nature and will be based on BI standards. No h ypothesis testing is plan ned.
Statistical analy sis and reporting of adverse events will concentrate on treatment -emergent 
adverse events, i.e. all adverse events occurring between start of treatment and end of the 
REP.Adverse events that start before first drug intake and deteri orate under treatment will 
also be considered as ‘treatment- emergent’.
Frequency , severit y, and causal relationship of adverse events will be tabulated b y system 
organ class and preferred term after coding according to the current version of the Medical 
Dictionary  for Drug Regulatory  Activities (MedDRA) at database lock .

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 66of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Laboratory  data will be analy sedboth quantitatively  as well as qualitatively. The latter will 
be done via comparison of laboratory data to their reference ranges. Values outside the 
reference range as well as values defined as clinically  relevant will be summarised . Treatment 
groups wil l be compared descriptivel y with regard to distribution parameters as well as with 
regard to frequency  and percentage of subjects with abnormal values or clinically  relevant 
abnormal values.
Vital signs, ph ysical examinations, or other safet y-relevant dat a observed at screening, 
baseline, during the course of the trialand at the end -of-trialevaluation will be assessed with 
regard to possible changes compared to findings befo re start of treatment.
7.2.6 Other Analyses
Details of other anal yses, if needed, will be included in the TSAP.
7.2.7 Interim Analyses
Nostatistical interim analy sis is planned. However, after completion of the 400mg dose 
group the independent Investigator and BI medical representative swill review blinded 
photosafet y data of treatment A group to determine the acceptability  of photo safet y. After the 
team review ofthese data , itmay be recommend ed, or in case of unfavourable results -to test 
the higher dose of 300mg BID for treatment A .In addition, a preliminary  blinded PK anal ysis 
will be performed to estimate the PK exposure.
7.3 HANDLING OF MISSING 
DATA
No imputation is planned for missing MED, PI, or assessments of skin reaction data.
7.4 RANDOMISATION
Thefirstset of subjects will be first randomised to the Treatment A (BI 400 mg QD/placebo) 
or Treatment B group in a3:1ratio. The random list will be provided by  BI to the dedicated
study  staff. 
Subjects allocated to the treatment group A will be randomised in a3:1ratio in a double blind 
manner , which reflects the ratio of subjects receiving active drug to placebo.
Subjects allocated to treatment B group will receive ciprofloxacin.
In order to investigate a second BI730357 dose of 300 mg BID, a second set of subjects be 
randomised in a 3:1 ratio in the same double blind manner described for Treatment A above, 
which reflects the ratio of subjects receiving active drug to placebo.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 67of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019BI will arrange for the randomi sation as well as packaging and labelling of trialmedication
for treatment A . The randomi sation list will be generated using a validated sy stem, which 
involves a pseudo- random number generator so that the resulting treatment will be both 
reproducible and non- predictable. The block size will be documented in the C linical Trial 
Report . Access to the codes wil l be controlled and documented.
More details can be found i n section 4.1.5 .
7.5 DETERMINATION OF SAM PLE SIZE
It is planned to include initially a total of 84healthy  male and female subjects (36 subjects for
Treatment A400 mg QD, 36 subject for Tretment A 300 mg BID ; 12 subjects forTreatment
B)in this trial .
The planned numbers of subjects should be sufficient for the exploratory  evaluation of photo-
safet yof each of the BI 730357 dose groups .  Based on a similarly  designed study  for 
evaluation of pradigastat the obse rved mean ( standard deviation) over all PI measur ements 
for 9 patients who received placebo and 12 
subjects who received ciprofloxacin was 1.08 
(0.12) and 1.61 ( 0.55) , respectively  (R19-3037 ).  
Assuming a common standard deviation of 0.15 and an expected difference in mean PI of 0 
between BI 730357 and placebo, each of the two group 0.05 one -sided t-tests will have 99% 
power to reject the null hypothesis that BI 730357 and placebo are not equivalent (the 
difference in means, µBI-µpbo, is ≥ 0.4 and µBI-µpbo≤ -0.4) in favor of the alternative 
hypothesis that the means of the two groups are equivalent (nQuery  Advisor, version 7).
Additionally , for the planned comparison of mean PI s for BI 730357 and ciprofloicin, a two 
group Satterthwaite t -test with a 0.05 two-sided significance level will have 87% power to 
detect a differ ence in means of 0. 6(the differ ence between 
µciproof 1.60and a µBIof 1.0) 
assuming standard deviation of ciprofloxacin is 0. 600 and standard deviation for BI 730357 is 
0.15 when the sampl e sizes in the two groups are 12 and 27 , respectivel y(nQuery  Advisor, 
version 7) .  Using the same assumptions and calculation for 12 ciprofloxacin and 9 placebo 
instead of 27 BI 370357 subjects the power is 86%.
  Based on the similar study  of 
pradigastat, the drop -
out rate will be minimal. Further details w ill be discussed  in the TSAP.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 68of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20198. INFORMED CONSENT, TRIAL RECORDS , DATA 
PROTECTION, PUBLICATION POLICY , AND
ADMINISTRATIVE STRUCT URE
The trialwill be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the I CH Harmonized Guideline for Good 
Clinical Practice (GCP) , relevant BI Standard Operating Procedures (SOPs), the EU directive 
2001/20/EC / EU regulation 536/2014 and other relevant regulations. Investigators and site 
staff must adhere to these principles. D eviation from the protocol, the principles of I CH GC P 
or applicable regulations as will be treated as “ protocol deviation” .
Standard medical care (prophy lactic, diagnostic and therapeutic procedures) remains the 
responsibility  of the treating phy sician of the patient.
The investigator will inform the sponsor immediately  of any  urgent safet y measures taken to 
protect the trialparticipants against an y immediate hazard, as well as of any  serious breaches 
of the protocol or of ICH GCP.
The Boehringer Ingelheim transparency  and publication policy  can be found on the following 
web page : trials.boehringer -ingelheim.com. The rights o f the investigator and of the sponsor
with regard to publication of the results of this trial are described in the investigator contract. 
As a rule , no trial results should be published prior to finali sation of the Clinical Trial Report .
8.1 TRIAL APPROVAL, PATIENT INFORMATION, INFORME D CONSENT
This trialwill be initiated only  after all required legal documentation has been reviewed and 
approved b y the respective Institutional Review Board (IRB / Independent Ethics Committee 
(IEC and competent authority  (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by  amendments.
Prior to 
patient participation in the trial , written informed consent must be obtained from each 
patient (or the patient ’s legally  accepted representative) according to ICH -GCP and to the 
regulatory  and legal requirements of the participating country . Each signature must be 
personall y dated b y each signatory  and the informed consent and any  additional patient -
information form re tained by  the 
investigator as part of the trialrecords. A signed copy  of the 
informed consent and any  additional patient information must be given to each patient or the 
patient ’s legall y accepted representative.”
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 69of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20198.2 D ATA QUALITY ASSURANCE
A risk- based approach isused for trialqualit y management . It is initiated by the assessment 
of critical data and processes fortrial subject protection and reliabilit y of the results as well as 
identification and assessment of associated risks. An Integr ated Qualit y and Risk 
Management Plan documents the 
rationale and strategies for risk management during trial 
conduct including monitoring approaches, vendor management and other processes focusing 
onareas of greatest risk .
Continuous risk review and assessment may lead to adjustments in trial conduct, trial design 
or monitoring approaches. 
A quality  assurance audit/inspection of this trialmay be conducted b y the sponsor ,sponsor ’s 
designees ,or by IRB /IECor by  regulatory  authorities. The quality  assurance auditor will 
have access to all medical records, the investigator ’s trial-related files and correspondence, 
and the informed consent documentation of this clinical trial .
8.3 RECORDS
CRF sfor individual subje ctswill be provided b y the sponsor .See section 4.1.5.2 for rules 
about emergency  code breaks. For drug accountability , refer to section 4.1.8 .
8.3.1 Source documents
In accordance with regulatory  requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trialrecords that include all observations and 
other data pertinent to the investigation on each trialpatient . Source data as well as reported 
data should follow the “AL COA principles” and be attributable, legible, contemporaneous, 
original and a ccurate. Changes to the data should be traceable (audit trail).
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be expl ained.
Before providing an y copy  of subjects
’ source documents to the sponsor , the investigator 
must ensure tha t all patient identifiers (e .g. patient ’sname, initials, address, phone number, 
social securit y number ) have properl y been removed or redacted from an y copy  of the 
subjects ’source documents.
If the subject is not compliant with the protocol , any  corrective action e.g. re -training must be 
documented in the subject file.
For theCRF, data must be derived from source documents, for example:
Subject identification : gender, year of birth (in accordance with local laws and 
regulations )
Subject participation in the trial(substance, trialnumber, patient number, date patient was 
informed)
Dates of Subject ’s visits, including dispensing of trialmedicati on
Medical history  (including trialindication and concomitant diseases, if applicable)
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 70of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Medication history
Adverse events and outcome events (onset date (mandatory ), and end date (if available))
Serious adverse events (onset date (mandatory ), and end date (if available))
Concomitant therap y (start date, changes)
Originals or copies of laboratory  results and other imaging or testing results, with proper 
documented medical evaluation (in validated electronic format, if available)
Completion of Subject ’s participation in the trial”(end date; in case of premature 
discontinuation document the reason for it).
Prior to allocation of a Subject to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet an y exclusion criteria. The absence of 
records (either medical records , verbal documented feedback of the Subject or testing 
conducted specific for a protocol) to support inclusion/exclus ion criteria does not make 
the Subject eligible for the clinical trial.
8.3.2 Direct access to source data and documents
The investigator /institution will allow site trial-related monitoring, audits, IRB /IEC review 
and regulatory  inspections. Direct access must be provided to the CRF and all source 
documents/data, including progress notes, copies of laboratory and medical test results, which 
must be available at all times for review b y the CRA , auditor and regulatory  inspector 
(e.g. FDA). They  may  review all CRFs and informed consents. The accuracy  of the data will 
be verified b y direct comparison with the source documen ts described in section 
8.3.1. The 
sponsor will a lso monitor compliance with the protocol and GCP.
8.3.3 Storage period of records
Trial site(s):
The trialsite(s) must retain the source and essential documents (including ISF) according to 
contract or the local requirements valid at the time of the end of the trial (whatever is longer).
Sponsor :
The sponsor must retain the essential documents according to the sponsor ’s SOPs.
8.4 EXPEDITED REPORTING OF  ADVERSE EVENTS
BI is responsible to fulfil their legal and regulatory  reporting obligation 
in accordance with
regulatory  requirements. 
Exemptions from expedited reporting are described insection 5.2.6.2.4, if applicable .
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 71of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20198.5 STATEMENT OF CONFIDE NTIALITY AND PATIENT PRIVACY
Data protection and data securit y measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 7 and 12 of the WHO GCP 
handbook.
Individual patient data obtained as a result of this trialis considered confidential and 
disclosure to third parties is prohibited with the following exceptions:
Personalised t reatment data may  be given to the patient’s personal ph ysician or to other 
appropriate medical personnel responsible for the patient ’s we lfare. Data generated at the site
as a result of the trialneed to be available for inspection on request b y the participating 
physicians, the sponsor ’s representatives, by  the IRB / IEC and the regulatory  authorities.
8.5.1 Collection, storage and future use o f biological samples and corresponding 
data
Measures are in place to comply  with the applicable rules for the collection, biobanking and 
future use of biological samples and clinical data, in particular
Sample and data usage has to be in accordance with t he separate biobanking informed 
consent
The BI -internal facilities storing biological samples from clinical trial participants as 
well as the external banking facility  are qualified for the storage of biological samples 
collected in clinical trials
An appropriate sample and data management sy stem, incl. audit trail for clinical data 
and samples to identify  and destroy  such samples according to ICF is in place
A fit for the purpose documentation (biomarker proposal, anal ysis plan and report) 
ensures compliant usage
A fit for purpose approach will be used for assay /equipment validation depending on 
the intended use of the biomarker data
Samples and/or data may be transferred to third parties and other countries as 
specified in the biobanking ICF
8.6 TRIAL MILESTONES
The start of the trial is defined as the date when the first subject in the whole trialsigns 
informed consent .
The end of the trial is defined as the date of the last visit of the last subject in the whole trial
(“Last Patient Completed ”).The “ Last Patient Last Treatment ”(LPLT ) date is defined as 
the date on which the last patient in the whole trial is administered the last dose of trial 
treatment (as scheduled per protocol or prematurely ). Individual investigator s will be notified 
of SUSARs occurring with the trialmedication until 30 day s after LPLT at their site.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 72of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Early termination of the trial is defined as the premature termination of the trialdue to an y 
reason before the end of the trialas specified in thi s protocol.
Temporary halt of the trial is defined as an y unplanned interruption of the trialby the 
sponsor with the intention to resume it.
Suspension of the trial is defined as an interruption of the trial based on a Health Authority  
request.
A final re port of the clinical 
trialdata will be written only  after all subjects have completed 
the trial to incorporate and consider all data in the report.
8.7 A DMINISTRATIVE STRUCTURE OFTHE TRIAL
The trialis sponsored b y Boehringer Ingelheim (BI).
The trial will be conducted at one clinical site. A Principal Investigator is responsible to 
coordinate co -investigators at thesite participating in this trial. Tasks and responsibilities are
defined in a contract. 
Relevant documentation on the participating Investiga tors (e.g. their curricula vitae ) will be 
filed in theISF.
BIhas appointed a Clinical Trial Leader (CT Leader ), responsible for coordinating all 
required activities, in order to 
-manage the trial in accordance with applicable regulations and SOPs applicable in a 
FOT setting ,
-direct the clinical trial team in the preparation, conduct, and reporting of the trial,
-ensure appropriate training and oversight of the vendors.
The organisation of the trialwill be performed b y a Contract Research Organisation (CRO) 
with which the responsibilities and tasks will have been agreed and a written contract filed 
before initiation of the clinical trial.
CRO will perform Project Management, Clinical Field Monitorin g, Medical Monitoring,
Data Management, Statistical Evaluation and Reporting. 
Tasks and functions assigned in order to organise, manage, and evaluate the trialaredefined 
according to BI and CRO SOPs. A list of responsible persons and relevant local in formation 
can be found in the ISF.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 73of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 20199. REFERENCES
9.1 PUBLISHED REFERENCES
R19-2246 Highlights of prescribing information, CI PRO (ciprofloxacin hy drochloride) 
tablet, for oral use.
R
19-3127 Ciprofloxacin US PI  03 -2019
R19-2247 S10 Photosafet y Evaluation of Pharmaceuticals. Guidance for Industry.
R
19-3037  
TheDGAT 1inhibitor pradigastat does notinduce photosensitivity  in healthy  
human subjects: a randomized controlled trial using three defined sunlight 
exposure conditions. Photochem Photobiol Sci 15 (9), 1155 -1162 (2016)
9.2 UNPUBLISHED REFERENC ES
001-MCS - 36 -472 Standards and processes for analy ses performed within Clinical 
Pharmacokinetics/Pharmacod ynamics. Current version.
c09228382 Investigators´s Brochure. BI 730357. Psoriasis (anky losing spondy litis, 
psoriatic arthritis, asthma, inflammatory  bowel disease) . Current version.
n00250111  
Prediction of BI 730357 Pharmacokinetics and Therapeutic Dose in Human. 
Current version.

Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 74of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201910. APPENDICES
10.1 RESTRICTED MEDICATIO N AND FOOD 
Other investigational products•30 days or 5 half-lives , what ever is longer, pr ior 
to randomization through EOT
Disease , surgery •Major surgery performed within 8 weeks prior 
to screening visit or planned within 8weeks
after screening visit (e.g. hip replacement)
-Drugs or foods (e.g., seville oranges, 
grapefruit, paw paw and their products) which 
arestrong or moderate inhibitors or inducers of 
CYP3A4 (e.g, rifampicin, phenytoin), or
-Sensitive substrates of CYP 1A2 (e.g., 
alosetron, duloxetine, melatonin, ramelteon, 
tasimelteon, theophylline, tizanidine, and 
caffeine when used as a medication), or 
-Sensitive substrates of CYP 2B6 (e.g., 
bupropion).•One week prior to randomisation until EOT
(Sensitive substrates of CYP3A4 are not 
excluded from the trial ).
Drugs which are substrates of P -gp (e.g. 
dabigatran, digoxin and fexofenadine etc.)•One week prior to randomisation until EOT
Drugs with known phototoxic or photoallergic 
potential
(e.g., tetracyclines, fluoroquinolones )•One week prior to randomisation until EOT
BCG (Bacillus Calmette- Guérin) vaccine •1 year prior to randomisation through 1 year 
after last administration of study drug
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 75of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201910.2 T IME SCHEDULE FOR PHA RMACOKINETIC (PK) BL OOD 
SAMPLING
Table 10.2: 1 Time schedule for PK blood sampling during treatment course A 400 
mg QD
Day Time Point 
[hh:min]1CRF 
Time
/PTMEvent Sample 
No.
1 Just before drug 
administration-1:00 PK Blood 1
0:00 0:00 1stDrug 
administr.---
4:00 4:00 PK Blood 2
2 8:00/Predose 24:00 PK Blood 3
3 8:00/Predose 48:00 PK Blood 4
4 8:00/Predose 72:00 PK Blood 5
5 8:00/Predose 96:00 PK Blood 6
6 8:00/Predose 120:00 PK Blood 7
7 8:00/Predose 144:00 PK Blood 8
8 8:00/Predose 168:00 PK Blood 9
9:00 169:00 PK Blood 10
10:00 170:00 PK Blood 11
11:00 171:00 PK Blood 12
12:00 172:00 PK Blood. 13
14:00 174:00 PK Blood 14
20:00 180:00 PK Blood 15
9 8:00 192:00 PK Blood 16
10 8:00 216:00 PK Blood 17
11 8:00 240:00 PK Blood 18
1 Time windows allowed for PK sampling:
Within 1 h pre -dose and 4 h post dose on day  1; -10 min pre -dose samples on day s 2 to 8; +/ -
5 min 1/2/3/4/ 6/12 h on day 8; +/ -15 min on day s 9/10/11. 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 76of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019Table 10.2: 2 Time schedule for PK blood sampling during treatment course A 300 
mg BID
Day Time Point 
[hh:min]1,2CRF 
Time
/PTMEvent Sample 
No.
1 Just before drug 
administration-1:00 PK Blood 1
8:00 0:00 1stDrug 
administr.---
9:00 1:00 PK Blood 2
10:00 2:00 PK Blood 3
11:00 3:00 PK Blood 4
12:00 4:00 PK Blood 5
14:00 6:00 PK Blood 6
16:00 8:00 PK Blood 7
18:00 10:00 PK Blood 8
20:00 12:00 PK Blood 9
5 8:00/Predose 96:00 PK Blood 10
6 8:00/Predose 120:00 PK Blood 11
7 8:00/Predose 144:00 PK Blood 12
8 8:00/Predose 168:00 PK Blood 13
9:00 169:00 PK Blood 14
10:00 170:00 PK Blood 15
11:00 171:00 PK Blood 16
12:00 172:00 PK Blood. 17
14:00 174:00 PK Blood 18
20:00 180:00 PK Blood 19
9 8:00 192:00 PK Blood 20
10 8:00 216:00 PK Blood 21
11 8:00 240:00 PK Blood 22
1 Time windows allowed for PK sampling:
Within 1 h pre -dose  and 4 h post dose on day 1; -10 min pre -dose samples on day s 5to 8; +/-
5 min 1/2/3/4/12 h on day 8; +/ -15 min on day s 9/10/11. 
2 All timepoints are relative to the drug administration time.
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 77of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201911. DESCRIPTION OF GLOBA L AMENDMENT(S)
11.1 GLOBAL AMENDMENT 1
Date of amendment 05Mar 2020
BI Trial number 1407-0037
BI Investigational Medicinal 
ProductBI 730357
Title of protocol Partially -blind, randomized, parallel group, placebo 
and active comparator -controlled Phase I clinical 
trial to evaluate the photosensitivity  potential of BI 
730357
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard –IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed 4.1.5.1 Blinding; 
7.2.7 I nterim anal ysis;
Description of change The following sentence was added on page 38:
In addition, the trial pharmacokineticist may  receive 
the blinded (dummy  subject numbers will be used) 
results of the measurements to perform the 
preliminary  PK anal ysis.
The following sentence was added on page 6 2:
In addition, a preliminary blinded PK analy sis will 
be performed to estimate the PK exposure.
Rationale for change The administrative amendment is incorporated to 
allow preliminary  analy sis of blinded PK data. The 
results from the blinded PK analy sis will be 
compared with the historical data upon which the 
study  was designed. This blinded evaluation 
possibility  was ov erseen in the original protocol, 
and is now added per this non -substantial 
amendment  
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 78of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 201911.2 GLOBAL AMENDMENT 2
Date of amendment 01 Apr 2020
BI Trial number 1407 -0037
BI Investigational Medicinal 
ProductBI 730357
Title of protocol Partially -blind, randomized, parallel group, placebo 
and active comparator -controlled Phase I clinical 
trial to evaluate the photosensitivity  potential of BI 
730357
To be implemented only after approval of the IRB / IEC / Competent 
Authorities
To be implemented immediately in order to eliminate hazard –IRB / IEC / 
Competent Authority to be notified of change with request for approval
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only
Section to be changed Synopsis; Flow chart 300 mg BID; 
1.4.2 Risks; 
3.1 Overall Trial Design; 3.2 Discussion of Trial 
Design; 
4.1.1 I nvestigational Treatments;
4.1.2 Selection of doses in the trial and dose 
modifications
7.5 Determination of Sample size analy sis;
Description of change Additional dose group 300 mg of BI 730357 or 
Placebo BID has been added.
Rationale for change Results of the Week 12 primary  anal ysis for trial 
1407- 0030 demonstrate dproof -of-concept , as well 
as acceptable safet y and tolerability inthe treatment 
of patients with moderate -to-severe plaque PsO for 
BI 730357 at the 200 mg dose;
Modelling of primary  analy sisdata indicates that the 
efficacy  plateau of BI 730357 may not hav e been 
reached with 200 mg dose q.d., and that higher 
exposur es may  provide better efficacy . Therefore
efficacy , safet y, tolerability , and pharmacokinetics 
of BI 730357 400 mg q.d. and 200 mg b.i
.d.will be 
Boehringer Ingelheim 01 Apr 2020
BI Trial No.: 1407-0037
c27983101
-03 Clinical Trial Protocol Page 79of 79
Proprietary confidential information © 2020 Boehringer I ngelheim I nternational GmbH or one or more of its affiliated companies
001-MCS -40-106_RD -03(17.0)/Saved on18Mar 2019evaluated as possible therapeutic doses in patients.
Psoriasis patients ha ve shown higher exposure s than 
those of health y volunteers; therefore in order to 
investigate possible phototoxic effects in exposures 
which approximate those of patients treated with 
200 mg b.i.d., health y volunteers will be treated with 
300 mg b.i.d. under fed conditions in thi s trial. 
   
 
APPROVAL / SIGNATURE PAGE 
 Document Number:  Technical Version Number:  
Document Name:  
  
                                                                                                                  
Title:  
 
 
 
                                                                                                                    
Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
   
 
  
  
   
 
  
  
 c27983101 3.0
clinical-trial-protocol-version-03
Partially-blind, randomized, parallel group, placebo and active comparator-controlled
Phase I clinical trial to evaluate the photosensitivity potential of BI 730357
Author-Clinical Trial Leader 01 Apr 2020 14:53 CEST
Author-Trial Statistician 01 Apr 2020 15:02 CEST
Author-Trial Clinical
Pharmacokineticist01 Apr 2020 16:00 CEST
Approval-Therapeutic Area 01 Apr 2020 16:19 CEST
Approval-Team Member Medicine 01 Apr 2020 18:37 CEST
Verification-Paper SignatureCompletion01 Apr 2020 18:38 CEST

Boehringer Ingelheim Page  2 of 2
Document Number:  Technical Version Number :  
 
 (Continued) Signatures (obtained electronically) 
 
Meaning of Signature  Signed by Date Signed 
 
   
  
 
 
  
  
  
 
  
 
    
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 c27983101 3.0